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 Neoplasms frequently present structural chromosomal aberrations that can alter 
the level of expression of a protein or induce the expression of an aberrant chimeric 
protein. Thyroid neoplasms are the most frequent type of endocrine tumours. The PAX8-
PPARG fusion is present in the neoplastic lesions that have a follicular morphology - 
follicular thyroid carcinoma (FTC), follicular variant of papillary thyroid carcinoma (FVPTC) 
and follicular thyroid adenoma (FTA), while the presence of RET/PTC fusions are largely 
restricted, among thyroid tumours, to papillary thyroid carcinoma (PTC). The present 
thesis was divided in two parts for the sake of clarity: in Part I, we studied the role of 
chromosomal rearrangements in different subtypes of epithelial thyroid tumours and, in 
Part II, we used a custom designed oligo microarray approach to study 548 known or new 
fusion genes in epithelial thyroid tumours. 
 In Part I, we studied ten PTCs composed of areas with papillary and follicular 
growth patterns. PAX8-PPARG rearrangements were exclusively detected in areas of 
follicular growth pattern, and RET/PTC rearrangements were detected in both papillary 
and follicular areas of the PTCs. Occasionally, we observed coexistence of RET/PTC 
rearrangements and BRAF mutations (p.V600E) that was significantly associated with 
areas of PTCs displaying papillary growth pattern. Additionally, we compared the 
clinicopathological and genetic features of nine multinodular PTCs (MNPTCs) and 17 
single nodule PTCs (SNPTCs). We confirmed that PAX8-PPARG rearrangements were 
restricted to the follicular patterned areas of MNPTCs and SNPTCs, and we found a 
higher frequency of chromosomal rearrangements (RET/PTC and PAX8-PPARG) in 
MNPTCs than in SNPTCs. The results we obtained in these two studies confirmed the 
close genotype-phenotype signature present in PTC, in which RET/PTC rearrangements 
are associated to papillary growth pattern, and PAX8/PPARG is restricted to areas of 
follicular growth pattern. Additionally, RET/PTC and PAX8/PPARG rearrangements and 
BRAF (p.V600E) and RAS mutations seem to represent subclonal events of tumour 
progression. SNPTC and MNPTC showed distinct clinicopathological and molecular 
profiles. MNPTCs are larger, occur in older patients and often present multiple molecular 
alterations, among which RET/PTC rearrangements are a frequent event. 
 The genotype-phenotype signature profile of oncocytic thyroid tumours still 
remains unclear. We studied the clinicopathological and genetic features of follicular 
Hürthle cell adenomas and follicular Hürthle cell carcinomas (FHCC). RET/PTC 
rearrangement was significantly associated with solid growth pattern in FHCC, and 75% of 
the FHCC that scored positive for PAX8-PPARG showed follicular growth pattern. Despite 
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being widely accepted that RET/PTC rearrangements are largely associated with PTC, 
our work study shows that oncocytic variant of FTC can also harbour this rearrangement. 
We discuss whether this association may be related or not with the oxidative milieu of 
Hürthle cell tumours. 
 Rare and genetically uncharacterized cases originated from well-differentiated 
follicular-cell derived thyroid tumours were also studied. The results obtained reinforce the 
role of the PAX8-PPARG rearrangements in the development of tumours with 
predominant follicular growth pattern. PAX8-PPARG rearrangement was detected in a 
rare malignant struma ovarii diagnosed as FVPTC and in a doubtful FTC with a previously 
undescribed glomeruloid growth pattern. A germline PAX8-PPARG rearrangement was 
identified in a patient with an autonomously hyperfunctioning FTC with angioinvasive 
features. 
 Although chromosomal rearrangements have been associated with some 
morphologic phenotypes of thyroid tumours, our results demonstrate that such association 
is not totally specific. Besides this, the genetic alteration(s) underlying a considerable 
percentage of thyroid epithelial tumours still remain(s) unknown. 
 In Part II, a comprehensive screen for 548 known and putative fusion genes in 27 
samples of thyroid tumours and three positive controls was performed using a oligo 
microarray approach. Only well known, previously reported fusion genes in thyroid 
oncology, were identified. Our results reinforce the role played by RET/PTC1, RET/PTC3 
and PAX8-PPARG fusion genes in thyroid tumourigenesis. Further studies using high-
throughput sequencing technologies should be performed in order to improve the 
detection of new fusion genes in thyroid tumours. 
 Summing up, in the present thesis we corroborated that: BRAF mutations 
represent a diagnostic molecular marker of malignancy in epithelial thyroid tumours, being 
particularly prevalent in PTC; PAX8-PPARG rearrangements are a useful molecular 
marker of thyroid tumours with follicular growth pattern; RET/PTC rearrangements and 
RAS mutations are found in different types of benign and malignant epithelial thyroid 
tumours, reinforcing that such genetic alterations cannot be identified, per se, as bona fide 
makers of histotype nor of malignancy. Other players, including other genetic alterations, 
as well as epigenetic and (micro)environmental factors, should be considered to 
understand the putative etiopathogenic role of RET/PTC and RAS mutations. 
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 As neoplasias apresentam frequentemente aberrações cromossómicas que 
alteram o nível de expressão proteica ou induzem a expressão de proteínas quiméricas 
aberrantes. As neoplasias da tiróide constituem o tipo de tumores endócrinos mais 
frequente. A fusão génica PAX8-PPARG está presente nas lesões neoplásicas que têm 
morfologia folicular – carcinoma folicular da tiróide (CFT), variante folicular do carcinoma 
papilar da tiróide (VFCPT) e adenoma folicular da tiróide (AFT), enquanto a presença das 
fusões génicas RET/PTC estão restritas, no universo dos tumores, ao carcinoma papilar 
da tiróide (CPT). Para tornar a leitura mais simples decidimos dividir a tese em duas 
partes: na Parte I, estudámos o papel dos rearranjos cromossómicos em diferentes 
subtipos de tumores epiteliais da tiróide; na Parte II, usámos uma abordagem baseada 
num oligo microarray personalizado para estudar 548 fusões génicas conhecidas, ou 
novas, em tumores epiteliais da tiróide. 
 Na Parte I, estudámos dez CPT compostos por áreas de padrão papilar e folicular. 
Os rearranjos cromossómicos PAX8-PPARG foram detectados exclusivamente nas áreas 
de padrão de crescimento folicular, enquanto os rearranjos cromossómicos RET/PTC 
foram detectados tanto nas áreas de padrão de crescimento papilar como folicular. 
Também observámos a coexistência de rearranjos RET/PTC e mutações BRAF 
(p.V600E) significativamente associada às áreas de padrão de crescimento papilar dos 
CPT. Adicionalmente, comparámos as características clinicopatológicas e genéticas de 
nove CPT multinodulares (CPTMN) e 17 CPT composto por nódulos únicos (CPTNU). 
Confirmámos que os rearranjos PAX8-PPARG estavam confinados às áreas de padrão 
de crescimento folicular dos CPTMN e dos CPTNU. Observámos também uma 
frequência elevada de rearranjos cromossómicos (RET/PTC e PAX8-PPARG) nos 
CPTMN comparativamente aos CPTNU. Os resultados obtidos nestes dois estudos 
confirmaram a existência de uma assinatura genotípica-fenotípica nos CPT, caracterizada 
pela demonstração de que os rearranjos RET/PTC estão associados ao padrão papilar, e 
os rearranjos PAX8-PPARG estão restritos às áreas de padrão folicular. Adicionalmente, 
os rearranjos RET/PTC e PAX8-PPARG e as mutações BRAF (p.V600E) e RAS parecem 
representar eventos subclonais na progressão tumoral. Os CPTMN e os CPTNU 
evidenciarem perfis clinicopatológicos e moleculares distintos com elevada prevalência 
dos rearranjos RET/PTC. 
 A assinatura genotípica-fenotípica dos tumores oncocíticos da tiróide permanece 
ainda por esclarecer. Estudámos as características clinicopatológicas e genéticas de 
adenomas foliculares de células Hürthle (AFCH) e de carcinomas foliculares de células 
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Hürthle (CFCH). Os rearranjos RET/PTC estavam significativamente associados ao 
padrão de crescimento sólido dos CFCH, enquanto 75% dos CFCH que eram positivos 
para os rearranjos PAX8-PPARG evidenciavam um padrão de crescimento folicular. 
Apesar de ser amplamente disseminado que os rearranjos RET/PTC estão associados 
aos CPT, o nosso trabalho mostrou que a variante oncocítica dos CFT pode também ter 
estes rearranjos. Discutimos se esta associação poderá estar relacionada, ou não, com o 
meio oxidativo dos tumores de células Hürthle. 
 Casos raros de tumores bem diferenciados que têm origem em células foliculares 
da tiróide, geneticamente não caracterizados, foram também estudados. Os resultados 
obtidos reforçam o papel dos rearranjos PAX8-PPARG no desenvolvimento dos tumores 
com padrão folicular predominante. Os rearranjos PAX8-PPARG foram detectados num 
caso raro de struma ovarii maligno, diagnosticado como VFCPT, e num caso duvidoso de 
CFT com um padrão de crescimento glomerulóide descrito pela primeira vez num 
carcinoma diferenciado da tiróide. Os rearranjos PAX8-PPARG foram também detectados 
na linha germinativa de um doente com um CFT autonomamente hiperfuncionante com 
características angioinvasivas. 
 Apesar dos rearranjos cromossómicos terem sido associados com alguns 
fenótipos morfológicos dos tumores da tiróide, os nossos resultados demonstram que tal 
associação não é totalmente específica. Além disso, numa percentagem considerável de 
tumores epiteliais da tiróide, a(s) alteração(ões) genética(s) subjacente(s) ainda 
permanece(m) desconhecida(s). 
 Na Parte II, realizámos uma pesquisa de 548 fuões génicas conhecidas ou 
hipotéticas em 27 amostras de tumores da tiróide e em três controlos positivos, usando 
uma abordagem baseada num oligo microarray. Apenas detectámos fusões génicas já 
conhecidas nos tumores da tiróide. Os nossos resultados reforçam o papel 
desempenhado pelas fusões génicas RET/PTC1, RET/PTC3 e PAX8-PPARG na 
tumorigénese tireoideia. Estudos adicionais, usando tecnologias de sequenciação high-
throughput serão realizados no futuro próximo de modo a melhorar a capacidade de 
detectar novas fusões génicas em tumores da tiróide. 
 Em conclusão, na presente tese confirmámos que: as mutações do oncogene 
BRAF representam um marcador molecular diagnóstico de malignidade em tumores 
epiteliais da tiróide; os rearranjos PAX8-PPARG são um marcador molecular associado a 
tumores da tiróide com padrão folicular; os rearranjos RET/PTC e as mutações do RAS 
são encontrados em diferentes tipos de tumores benignos e malignos da tiróide, 
reforçando a noção de que tais alterações genéticas não se podem considerar per se 
marcadores bona fide de tipo histológico ou de malignidade. Outros intervenientes, como 
 xxi 
 
alterações genéticas adicionais, assim como factores epigenéticos e (micro)ambientais, 
devem ser tomado em consideração para avançar na compreensão do papel possível 
etiopatogénico dos rearranjos RET/PTC e das mutações RAS. 
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Clinicopathological features of well-differentiated follicular-cell 
derived thyroid tumours 
 Thyroid cancer is the most frequent type of endocrine cancer with an incidence of 
12 cases per 100,000 individuals (1, 2) and the overall 5-year relative survival for 2002-
2008 was 97.5% (1). Patients with thyroid cancer have a median age of 50 years old (1), 
and the disease is more common among women than men. More than 95% of thyroid 
cancer cases are originated from thyroid follicular epithelial cells, that are involved in the 
regulation of cell metabolism by the biosynthesis of the iodinated hormones (T3 and T4) 
from thyroglobulin (Tg) (3). 
 Follicular cell-derived thyroid cancers are divided in three main groups, according 
to the differentiation state: well-differentiated thyroid carcinomas (WDTCs), poorly-
differentiated thyroid carcinomas (PDTCs) and undifferentiated (or anaplastic) thyroid 
carcinomas (UTCs). 
 The WDTCs comprises two main histotypes: papillary thyroid carcinoma (PTC) 
and follicular thyroid carcinoma (FTC). A differential diagnosis between FTC and a benign 
lesion - follicular thyroid adenoma (FTA), is provided by the evidence of capsular and/or 
vascular invasion on the FTC. 
 
Papillary thyroid carcinoma (PTC) 
 The diagnosis of PTC mainly relies on the identification of typical nuclei: large, 
irregular, clear, grooved, occasionally displaying pseudo inclusions (3, 4). PTC is the most 
common histotype of thyroid cancer usually with a good clinical behaviour carrying a 10 
years overall survival of 90-95% (5). PTC is more frequent in female patients with 20-50 
years old (3). PTC is frequently multinodular and gives rise to lymph node metastases (3). 
In irradiation context, namely in the setting of post-Chernobyl thyroid tumours PTCs are 
the most prevalent (90%) (6-8). PTC encompasses several histological variants (3), and 
we will describe briefly those that will be referred with more detail along this thesis. 
 
1 Introduction 
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Classical variant 
 Classical or conventional variant of PTC (cPTC) is the most common subtype. This 
variant is characterized by a predominant papillary growth pattern (Fig. 1A), or mixed 
(papillary/follicular) growth pattern (3).  
 Papillary architecture is complex with branching. The papillae are covered by 
epithelium with disturbed polarity and pale or eosinophilic cytoplasm (3). It is uncommon 
to find a pure papillary growth pattern, since other architectural patterns often coexist with 
papillae. The mixed growth pattern are usually composed of follicular structures, although 
it may also include solid and/or trabecular growth patterns (3). The cPTC is frequently 
multinodular and give rise to lymph node metastases 
 
Figure 1. A. Image of the histology of a classical papillary thyroid carcinoma (400x HE). B. Image of the 
histology of a follicular variant of papillary thyroid carcinoma (400X HE). C. Image of the histology of a 
follicular thyroid carcinoma (400X HE). 
 
Follicular variant 
 Follicular variant of PTC (FVPTC) presents a predominant follicular growth pattern 
(>95% of the tumour) maintaining the typical nuclear features of PTCs (Fig. 1B). FVPTC 
can present lymph node metastasis (3, 4), and less frequently, haematogenous 
metastasis can also occur (9). 
 One third of FVPTCs are encapsulated (3), and these neoplasms can be confused 
with FTA or FTC due the presence of the capsule and the organization in follicular 
structures. Prognosis of the FVPTC is similar to the cPTC (10), although multinodular or 
diffuse FVPTC can present a more aggressive clinical course (9, 11, 12). 
 
Solid-trabecular variant 
 Solid variant of PTC (solPTC) is characterized by solid sheets of tumour cells 
maintaining the typical nuclear features of PTC (3). This pattern is usually accompanied 
by a cord-like architectural arrangement of the cells – trabecular pattern. One third of 
cases present vascular invasion and extrathyroidal extension (3). 
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 SolPTCs are more common in children with a history of radiation exposure (13), as 
occurred in the tumours arising after Chernobyl nuclear accident where solid pattern was 
found in 34% of the tumours  (7). The prognosis tends to be very good to excellent, 
however the solPTC has a significant higher risk of relapse (14). 
 
Cribriform-morular variant 
 Cribriform-morular variant of PTC (CMVPTC) is characterized by focal papillary 
morphology, cribriform features, solid and spindle cell areas and squamous morules (3). 
CMVPTC predominate in female patients and usually appears as multiple tumours (15), 
although single nodule CMVPTC can occur (16). The CMVPTC is the typical form of 
familial adenomatous polyposis (FAP)-associated thyroid carcinoma (16), but it can also 
arise as sporadic form, associated with somatic mutations in beta-catenin (CTNNB1) or 
APC genes (17). 
 
Oncocytic variant 
 The oncocytic cells correspond to the mitochondria-rich follicular cells presenting 
eosinophilic and granular cytoplasm, also known as Hürthle cells, oxyphilic, oncocytic or 
Ashkenazy cells. 
 The diagnosis of oncocytic or Hürthle cell variant of PTC [papillary Hürthle cell 
carcinomas (PHCC)] must comprise two criteria: more than 75% of the neoplasm have to 
be composed of cells exhibiting oncocytic features, and nuclei should comprise the typical 
nuclear features of PTC (3, 4). PHCC can have papillary, follicular or mixed 
(papillary/follicular) morphology (3). 
 Some studies indicate PHCC with a more aggressive behaviour than cPTCs (18, 
19). 
 
Follicular thyroid adenoma (FTA) 
 FTA is usually a solitary round or oval nodule, surrounded by a fibrous capsule of 
variable thickness (3), without evidence of capsular or vascular invasion. The growth 
pattern of the FTA is distinct from the surrounding normal thyroid tissue (20) and 
cytological do not show the characteristic nuclear features of PTC. 
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 Appearance of the neoplasm can comprise microfollicular, normofollicular, 
macrofollicular, trabecular and (rarely) papillary morphologies, reflecting the size of the 
follicles and/or the growth pattern of the tumour cells. 
 
Oncocytic variant 
 Follicular Hürthle cell adenoma [(FHCA) or oncocytic variant of FTA] are tumours 
composed by large cells with eosinophilic and granular cytoplasm, hyperchromatic and 
pleomorphic nuclei and prominent eosinophilic nucleoli – Hürthle (oncocytic) cells. The 
designation FHCA applies when the tumour is composed exclusively or predominantly 
(more than 75%) by Hürthle cells, and there is no capsular or vascular invasion in the 
tumour nodule (3). 
 The pattern of growth is usually follicular, although and like other FTAs, FHCA can 
have a variety of morphological growth patterns - trabecular and/or solid (3). Papillary 
growth pattern can also arise, requiring a differential diagnosis of FHCA from PHCC 
based in the presence of typical nuclear features of PTC. 
 
Follicular thyroid carcinoma (FTC) 
 The follicular thyroid tumours (FTTs) - FTA, FTC and FVPTC, have similar clinical 
presentation and gross morphology: single nodules composed of follicles partially or 
totally rounded by a capsule. 
 FTC represents 10-15% of thyroid cancers (3), with a 10-year overall survival of 
75-80% (5). This malignancy occurs more frequently in female patients with 50-60 years 
old (3). 
 FTC exhibits follicle formation, lacking the typical nuclear features of PTC (Fig. 
1C). As aforementioned, differential diagnosis between FTC and FTA is based on the 
presence of capsular and/or vascular invasion (3, 20). FTC can also be sub classified in 
minimally invasive, when tumour shows focal capsular and/or vascular invasion and 
extensively invasive when there is major images of invasion. Morphologic appearance of 
FTC is variable, with follicular, solid, trabecular or mixed growth patterns. 
 
Oncocytic variant 
 Follicular Hürthle cell carcinoma [(FHCC) or oncocytic variant of FTC] accounts 
approximately 3% to 4% of thyroid carcinomas, with a 10-year relative survival rate of 
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76% (21). FHCC is a malignant neoplasm exclusively or predominantly composed (more 
than 75%) by Hürthle (oncocytic) cells that present capsular and/or vascular invasion (3, 
21-23). As occurs on FTC, FCHC can present difference histologic morphologies: 
follicular, solid and/or trabecular growth patterns. 
 FHCC is considered as a variant of FTC by the World Health Organization (3), 
although some authors describe FHCC as a separate entity (4).  
 There is a considerable percentage of cancer deaths in this context (24), that is 
usually attributed to the poor responsiveness of Hürthle cells to radioiodine therapy and to 
the frequent inclusion of cases of poorly differentiated carcinoma in the FHCC group (4, 
25). When FHCC and FTC without Hürthle cell features are stratified according to the 
extent of invasion there is no statistically significant difference in patients’ survival (26). 
 
Ovarian teratoma composed by thyroid tissue - struma ovarii 
 Struma ovarii (SO) is a rare monodermal form of ovarian teratoma in which more 
than 50% of the tumour is composed by thyroid tissue (27) and corresponds to 2.7% of all 
ovarian teratomas (28). The histologic appearance of SO mimics those of several thyroid 
lesions (from benign to malignant) (29, 30) being crucial, for diagnostic purposes, the 
identification of histological features of malignancy. 
 As in “cervical” thyroid tumours, when the morphologic features of SO correspond 
to normal tissue, goiter or adenoma, they are considered as benign SO (BSO) (31). When 
SO presents morphologic features of papillary thyroid carcinoma (PTC) or of follicular 
thyroid carcinoma (FTC), they are considered as malignant SO (MSO) (27). 
 MSO accounts for 5% to 10% of SO cases and 0.01% of all ovarian tumours (27). 
MSO can be categorized in 3 main subtypes: cPTC, FVPTC and FTC (3, 27, 32). The 
percentage of PTCs within MSO varies from 70% (32) to 85% of the cases (27); in the 
former series, 44% of the tumours were cPTC and 26% were classified as FVPTC (32). 
 SO with features of FTC are particularly difficult to diagnose since SO tumours 
frequently have irregular margins, lacking  a well-defined capsule (27), thus turning almost 
impossible to identify capsular or vascular invasion. Additionally, focal “PTC like” nuclear 
and cytological changes are often present, increasing the diagnostic difficulties, namely 
with regard to FVPTC, whose diagnosis relies almost exclusively in such nuclear features. 
These difficulties are evidenced by the wide variation of the prevalence of malignancy: 5 
to 37% of the cases in different SO series (27, 33). 
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Chromosomal rearrangements in well-differentiated follicular-cell 
derived thyroid tumours 
 Changes in gene expression in neoplasms frequently result from chromosomal 
translocations and can lead to change in the level of protein expression or to the 
expression of an aberrant chimeric protein. These structural chromosomal 
rearrangements are common in hematologic malignancies (34, 35), where the BCR-ABL1 
fusion gene is a classic example. In solid tumours, these genetic changes were 
considered rare. 
 The identification in thyroid tumours of the RET/PTC rearrangements (36), and of 
other types of specific chromosomal rearrangements such as PAX8-PPARG 
rearrangements (37), raised the epithelial thyroid tumours as a paradigm of carcinomas 
presenting chromosomal translocations (37-40). In the last few years, other examples of 
carcinomas with chromosomal rearrangements appeared, namely prostate and lung 
cancer, were identified (41, 42). Like in hematologic malignancies, where the BCR-ABL1 
fusion protein is specifically inhibited by Imatinib, the study of specific rearrangements that 
appear in solid tumours can boost the development of new targeted therapies. 
 
RET/PTC rearrangements 
 RET proto-oncogene is located on chromosome 10q11.2 encoding a receptor 
tyrosine kinase whose ligands belong to the glial cell line derived neurotrophic factor 
(GDNF) family (43). RET protein  includes an extracellular domain composed by four 
cadherin-like sites, a calcium-binding site and a cysteine-rich domain, a hydrophobic 
transmembrane region, and an intracellular domain containing the juxtamembrane domain 
and the tyrosine kinase domain (44). 
 In the thyroid gland, RET is highly expressed in parafollicular C-cells, but not in 
follicular epithelial cells, which is consistent with the role of RET in the development and 
function of neural crest-derived structures (45). 
 Besides the involvement of RET/PTC rearrangements in follicular-cell derived 
thyroid tumours (38, 46), point mutation which active RET are responsible for the 
development of inherited cancer syndromes, such as familial medullary thyroid carcinoma 
and multiple endocrine neoplasia type 2 (47-49) and inactivating germline RET mutations 
are found in cases of Hirschsprung disease (50, 51).  
 Thirteen different RET/PTC rearrangements have been described in human PTCs 
(52), differing from each other by their 5’ partner genes included in the chimeric oncogene 
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(53). These domains from different 5’ partner genes fuse with the tyrosine-kinase domain 
of RET. All breakpoints described in the RET gene occur within intron 11. All 5’ partners 
genes of RET/PTC rearrangements are expressed in thyroid follicular epithelial cells, 
providing a constitutive expression of RET chimeric protein in follicular cells, leading to the 
ligand-independent activation of the intact tyrosine-kinase domain of RET (53). 
 Most of the RET/PTC rearrangement isoforms are chromosomal translocations 
occurring between the RET gene on chromosome 10 and genes located in different 
chromosomes. However the two most frequent forms of rearrangement, RET/PTC1 
(CCDC6-RET) and RET/PTC3 (NCOA4-RET) (Fig. 2), are paracentric chromosomal 
inversions of chromosome 10 (36, 54, 55). 
 
Figure 2. Schematic drawing of the two most common RET/PTC variants - RET/PTC1 (alias CCDC6-
RET) and RET/PTC3 (alias NCOA4-RET). A. Both variants are paracentric chromosomal inversions of 
chromosome 10, and composed by different 5’ partner genes - CCDC6 or NCOA4, providing the 
promoter and the 5′ coding region. B. 5’- untranslated region and N-terminal encoding parts of CCDC6 
or NCOA4 fuse with the tyrosine-kinase (TK) domain of RET. Adapted from Pierotti et al. (56). 
 
 RET/PTC rearrangements are found in 20-40% of PTCs, the frequency differs with 
geographic localization (53), and with the method of detection applied (57). RET/PTC 
rearrangements are more frequent (45%-60%) in sporadic PTCs of children and young 
adults (58, 59) and in populations subjected to accidental or therapeutic irradiation (50%-
80%) (60, 61). 
 RET/PTC1 is the most common (43%) rearrangement followed by RET/PTC3 
(18%) (62), while the other eleven RET/PTC fusions are rare (less than 5%) and have 
been described in only few cases of radiation-induced PTCs (3, 52). 
 RET/PTC rearrangements are mostly detected in cPTC, FVPTC and solPTC (63-
67). Nikiforov et al. indicating that different types of RET/PTC rearrangements are 
associated with distinct phenotypes of PTC (68). The RET/PTC1 fusion genes is more 
common in sporadic cPTCs (65, 68, 69), whereas RET/PTC3 is more frequent in solPTCs 
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(65, 68, 69), with predominance in radiation-induced PTCs (65). The presence of multiple 
RET/PTC rearrangements at different locations within individual PTC samples can be an 
indication of tumour heterogeneity and multiclonality (70). 
 Some studies report the presence of RET/PTC rearrangements in FHCA (46, 71, 
72) and in FHCC (46, 71-73). Rarely, RET/PTC rearrangements have been detected in 
CMVPTC (74). Additionally, RET/PTC rearrangements have been detected in benign 
lesions of the thyroid (75), such as Hashimoto thyroiditis (73). 
 The presence of RET/PTC rearrangements was associated with lymph node 
metastasis and with a better prognosis (76, 77). However, other work did not detect any 
correlation between the clinicopathological features of PTC and positivity for RET/PTC 
rearrangement (78). The association of RET/PTC rearrangements with radiation exposure 
was highlighted by the high prevalence of RET/PTC rearranged PTC in young inhabitants 
of contaminated areas around Chernobyl (79).  
 There are some structural evidences that may justify the propensity for the 
formation of RET/PTC rearrangements. First, the nuclear chromatin organization in 
normal thyroid cells shows a close physical proximity of the CCDC6, NCOA4 and RET 
genetic loci, providing a structural basis for the formation of the RET/PTC1 and 
RET/PTC3 fusion genes (80-82). Second, the fragile sites FRA10C and FRA10G located 
on chromosome 10 next to CCDC6 and RET genes, respectively, might facilitate a 
mechanism for the generation of RET/PTC1 (83). Also, potent DNA damaging agents (as 
hydrogen peroxide) are able to induce RET/PTC1 rearrangements, suggesting that 
oxidative stress might be an additional mechanism facilitating RET/PTC1 rearrangement 
(84). 
 
NTRK1 rearrangements 
 NTRK1 gene is located on chromosome 1q21-22 encoding the high affinity 
receptor for nerve growth factor (beta polypeptide) (NGF). NTRK1 protein plays a critical 
role for development and maturation of central and peripheral nervous system and 
stimulates the proliferation (85). 
 Similarly to what occurs in RET/PTC rearrangements, all TRK fusion proteins 
maintain the NTRK1 tyrosine-kinase domain and, additionally, the five tyrosine residues 
that are crucial for NTRK1 activity (85). The formation of TRK fusion proteins leads to the 
ectopic expression of the fusion protein on the cytoplasm of the thyroid follicular epithelial 
cells, and the constitutive dimerization is mediated by coiled-coil domains, leading to 
constitutive kinase activity (85). 
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 The most frequent fusion gene involving NTRK1 gene is a paracentric inversion of 
the chromosome 1 fusing the TPM3 gene (1q22-23) with the kinase domain encoded by 
NTRK1 gene - TRK fusion gene (86, 87). Two other paracentric inversions of 
chromosome 1 involving NTRK1 are TRK-T1 and TRK-T2 fusion genes, being activated 
by different portions of the TPR gene (1q25) (88-90). TRK-T3 fusion gene is activated by 
a chromosomal translocation that fuses NTRK1 gene and TFG gene (3q11-12) (91). 
 NTRK1 rearrangements are found in 0-13% of PTCs (61, 92-97), with similar 
frequencies in sporadic and radiation-induced PTCs (92). It was found that PTC patients 
with NTRK1 rearrangement had a worse prognosis when compared to patients with RET 
rearrangement or without any rearrangement (95). However, this study included relatively 
few patients and is the only report attributing clinicopathological significance to the NTRK1 
rearrangement. 
 Some aforementioned data have suggested that the spatial proximity of the genes 
involved in the chromosomal rearrangement may favour gene rearrangements (80-82). It 
was demonstrated that the distance between NTRK1 and TPR genes in thyroid follicular 
epithelial cells is shorter compared to fusion prone loci in lymphocytes, suggesting that 
loci proximity may favour the propensity for the formation of NTRK1 rearrangements, in 
thyroid (98). 
 
BRAF rearrangements 
 BRAF proto-oncogene encodes a protein belonging to a family of RAF 
serine/threonine protein kinases (99). The protein plays a central role in the transduction 
of signal along the RAS/RAF/MEK/MAPK pathway, regulating cell growth, differentiation, 
and apoptosis (99). BRAF point mutations are well described in human cancer being the 
mutation p.V600E the most common (100). In thyroid tumours, BRAF mutation (p.V600E) 
is a common event found in PTC (36-69%) (101, 102), and will be discussed further 
below. 
 The BRAF gene can also be involved and activated in thyroid tumorigenesis by 
chromosomal rearrangements. A paracentric chromosomal inversion on chromosome 7, 
[inv(7)(q21–22q34)], has been reported in PTC, resulting in an in-frame fusion 
between exons 1–8 of the AKAP9 gene and exons 9–18 of the BRAF gene, located on 
7q21–q22 and 7q34 , respectively (103). The AKAP9-BRAF fusion protein contains the 
intact kinase domain and lacks the auto-inhibitory N-terminal portion of BRAF (103). 
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 AKAP9-BRAF rearrangement was only found in 1% of sporadic PTCs and in 
11% of post-Chernobyl PTCs (103), suggesting that constitutive activation of BRAF 
through chromosomal rearrangements occurs preferentially in irradiation context. 
 
PPARG rearrangements 
 A specific balanced translocation, t(2;3) (q13;p25) was reported in FTA and FTC 
(104, 105). The genes involved in this chromosomal translocation were first described in 
FTC (37). This chromosomal translocation fuses the promoter and proximal 5’ coding 
sequence of PAX8 gene with the entire translated reading-frame of the PPARG gene, 
leading to the translation of the PAX8-PPARG fusion protein (Fig. 3). 
 
Figure 3. Schematic drawing of the PAX8-PPARG rearrangements. A. Illustration of the PAX8-PPARG 
mRNA variants with exons arrangement and sites of fusion. The PAX8 activation domain (AD) is 
eliminated in all fusion events. B. Protein structure of the predicted fusion protein: contains the PAX8-
paired domain, containing the DNA binding domain (DBD), the octapeptide motif (OP), and the truncated 
homeodomain (HD). All of the functional domains of PPARG gene, including activation domains 1 and 2 (AD1 
and AD2), DBD, and ligand binding domain are retained in the fusion protein. Adapted from Placzkowski et al. 
(106). 
 
 PAX8 is a transcription factor important in thyroid follicular cell differentiation and in 
the regulation of a number of thyroid-specific genes (107). PPARG is part of a sub-family 
of the steroid/thyroid hormone nuclear receptor superfamily and it has an important role in 
adipogenesis and in insulin sensitization (108, 109). PPARG also play a role in cell cycle 
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control, apoptosis inflammation, atherosclerosis and carcinogenesis, through its influence 
on gene expression involving multiple cell signalling pathways (108, 109). 
 Several PAX8-PPARG splice variants have been identified, which appear to be 
frequently co-expressed (37, 107, 110, 111). All fusion variants described include the 
paired and partial homeobox DNA binding domains of PAX8, as well as the DNA binding, 
ligand binding, retinoid X receptor dimerization and transactivation domains of PPARG 
(37). 
 Recently, another chromosomal translocation was described involving the PPARG 
gene in FTC. CREB3L2-PPARG fusion gene results from a t(3;7)(p25;q34) chromosomal 
rearrangement encoding a protein containing the transactivation domain of CREB3L2 and 
the entire translated reading-frame of the PPARG (112). Additionally, a 
t(2;20;3)(p21;q11.2;p25) chromosomal translocation has also been observed in one FTA, 
in which a sequence of PPARG is fused to exon 28 of the thyroid adenoma associated 
(THADA) gene, its function is unknown (113). 
 It was demonstrated that the PAX8-PPARG chimeric protein does not stimulate 
thiazolidinedione-induced transcription and can inhibit the wild-type PPARG transcriptional 
activation (37). 
 Another in vitro study supports the evidence that the PAX8-PPARG fusion protein 
can act as an oncogene, since its expression results in an increase in cell cycle transition, 
reduction in apoptosis, loss of contact inhibition and matrix-independent growth (114). 
Additional studies demonstrated an increase of cell viability after PAX8-PPARG 
transfection (115), and an enhanced cell growth (116). Additionally, it was demonstrated 
that over-expression of both PAX8-PPARG and CREB3L2-PPARG stimulates the 
proliferation of primary human thyroid cells (112), suggesting that the entire translated 
reading-frame of PPARG is an essential component of these fusion genes with a 
dominant oncogenic mechanism of action. These effects appear to be mediated, at least 
in part, by wild-type PPARG inhibition (37, 114-117). However, it was found an up-
regulation of the expression of several PPARG targets genes in FTC with positivity for 
PAX8-PPARG rearrangement, such as angiopoietin-like 4 and aquaporin 7 (118). In 
addition, at least in vitro and under some circumstances, PAX8-PPARG can exert 
independent, ligand-responsive transcriptional activation from both PAX8- and PPARG-
responsive promoters (116). 
 Taking all the data together, further studies will be necessary to establish the 
mechanisms for each PAX8-PPARG actions and which of them contribute for PAX8-
PPARG -mediated tumorigenesis. 
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 PAX8-PPARG rearrangement is found in sporadic FTTs: FTA (0-55%), FTC (0-
63%), FVPTC (0-38%) and in FHCC (0-4%) (37, 40, 106, 107, 111). Conversely, PAX8-
PPARG rearrangement has not been described in normal thyroid tissue, benign lesions, 
cPTC and UTC (106) 
 PAX8-PPARG rearrangement in thyroid tumours from irradiation context was, as 
far as we know, investigated in a single report (111). In a group of patients exposed to 
radiation in Chernobyl, it was found the presence of the PAX8-PPARG rearrangement in 
FTAs (13%) and in FTCs (100%) (111). There are no reports disclosing the detection of 
PAX8-PPARG rearrangement in PTC from irradiation context. 
 PAX8-PPARG rearrangement was significantly associated with multifocality of the 
tumours and vascular invasion (40, 111). Moreover, it was shown that FTCs positive for 
PAX8-PPARG rearrangement were more frequently invasive (vascular) (119), suggesting 
that PAX8-PPARG rearrangement confers invasive potential to the FTC. These results 
support the idea that FTC develop through at least two distinct molecular pathways 
initiated by either PAX8-PPARG rearrangement or RAS point mutation (119, 120). 
However, other reports showed that FTC patients with negative expression PPARG 
protein presented more poorly differentiated areas and are more likely to have metastatic 
disease (121, 122). 
 
Point mutations in well-differentiated follicular-cell derived 
thyroid tumours 
 Initial studies reported that RET/PTC rearrangements in epithelial thyroid tumours 
were mutually exclusive regarding other genetic events, as point mutations on BRAF and 
RAS genes. RET/PTC rearrangements, BRAF or RAS mutations altogether were found in 
about 70% of cases (102, 123). However, later works reported some cases of epithelial 
thyroid tumours harbouring multiple molecular alterations – RET/PTC, BRAF and/or RAS 
mutations (66, 124-129). Particularly, the coexistence of PAX8-PPARG rearrangements 
with other genetic events have been less explored in thyroid tumours. Concomitant 
detection of PAX8-PPARG rearrangements and RAS mutations was found in FTTs (40, 
119). 
 
BRAF mutations 
 The BRAF mutation (p.V600E) is the most prevalent (29-69%) point mutation 
present in PTC (2, 130), and this molecular alteration is closely associated to papillary or 
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mixed papillary/follicular architecture of cPTC (131). BRAF mutation (p.V600E) leads to 
the constitutive activation of BRAF kinase and stimulation of the MAPK pathway, and is 
tumorigenic for thyroid cells. In contrast to cPTC, FVPTC shows other different BRAF 
mutations - BRAF (p.K601E) (131), BRAF [p.T599I-VKSR(600-603)del] (132) and BRAF 
(p.A598V) (133), but in at a lower prevalence (131). BRAF mutation (p.V600E) can also 
be found in 0-13% of PDTC and 10-35% of UTC (2, 134-136). 
 BRAF point mutations were associated with older age in patients with PTCs (131, 
134), and with extrathyroidal invasion of PTCs (134, 137). Point mutations in BRAF are 
not related with radiation exposure (138, 139). Although there are several associations 
between the presence of BRAF mutations and PTC recurrence, mortality and resistance 
to radioiodine therapy (135, 140, 141), the prognostic value of the BRAF mutations per se 
remains uncertain. The prognostic significance of the BRAF mutation is more difficult to 
prove if one takes into account the influence of other clinicopathological features, namely 
the papillary and follicular growth patterns of the tumours (131). 
 
RAS mutations 
 RAS mutations are found in about 30% of all human cancers (142). The three 
human RAS genes - HRAS, KRAS, and NRAS, encode highly related G-proteins that 
propagate signals arising from cell membrane receptors to various intracellular targets 
(143). Activating point mutations are common in codons 12, 13 and 61 of the RAS genes, 
and in thyroid cancer, mutation in codon 61 of NRAS and HRAS mutations are the most 
common (144). These mutations result in permanent RAS activation and stimulation of its 
downstream targets along the MAPK and PI3K/AKT signalling pathways (143). On thyroid 
tumours, the presence of RAS mutations are associated with the neoplasms with follicular 
growth pattern, with a prevalence of 24-53% have been reported in FTA (145), 40-53% in 
FTC (2), and 17-43% in FVPTC (40, 63, 67, 146). RAS mutations have also been reported 
in 18-27% of PDTC and 20-60% of UTC (2). 
 The clinical significance of RAS mutations in thyroid cancer is controversial. Some 
reports show that RAS mutations associated with aggressive phenotypes of the tumour 
and poor prognosis (147, 148), while others do not confirm this association (135). RAS 
mutation may be important in progression from WDTC to PDTC (149). However, it has 
been found similar prevalence of RAS mutations in benign and malignant thyroid tumours, 
suggesting that it can represent an early event in thyroid tumorigenesis (150). 
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Detection of fusion genes in tumours  
 Fusion genes are originated by structural chromosomal rearrangements such as 
translocations, inversions and deletions (151). Detection of fusion genes in cancer is 
arduous and time-consuming, usually includes chromosome banding analysis 
(karyotyping) followed by fluorescence in situ hybridization (FISH) studies and molecular 
analyses based on the reverse transcriptase polymerase chain reaction (RT-PCR) (151, 
152). Karyotyping allows the screening of rearrangements at the chromosomal resolution 
level. However, this approach implies the use of fresh biological samples or even culture 
of cells to obtain metaphase chromosomes, taking several days to obtain enough biologic 
material to proceed with chromosome banding analysis. Furthermore, only a fraction of 
the samples are successfully cultured, and thus, for many samples, no results are 
obtained. FISH approach can be used for the specific detection of numerical and 
structural chromosomal abnormalities that may occur in tumours and it is particularly 
useful as a tool for the diagnosis of non-random translocations in several cancers (153). 
FISH can be used in cells in interphase or in metaphase. Together with FISH approach 
targeting specific locus, RT-PCR is a method used to detect specifically one or few 
candidate fusion genes at known breakpoints regions. Both FISH and RT-PCR require 
prior knowledge of the suspected diagnosis to allow selection of the fusion genes to be 
searched. It is clear that the techniques looking for specific fusion genes have a great 
limitation: the incapacity to screen a large number of fusion genes. 
 Although high-throughput sequencing of cancer genomes can reveal very precise 
result about fusion genes, it is not an easy task to obtain sequence data. RNA-sequencing 
has been used to identify novel fusion genes, using several algorithms and tools to find 
the new fusion genes from the raw sequence data, where some of the bioinformatics tools 
are PER alignments (154), MapSplice (155), deFuse (156), FusionFinder (157), and Suffix 
Array Spliced Read fusion finder (158). This technology is yet limited in the number of 
samples that can be analyzed within a reasonable time-frame and/or at an acceptable 
cost. 
 Few studies have used oligo microarrays targeting junction sequences to detect 
fusion transcripts (159-162). A custom designed oligo microarray which covers detection 
of all possible chimeric exon-exon transcript breakpoint between known or suspected 
fusion partners has been recently developed (163). The analysis can be performed in a 
single experiment and no upfront assumption of the particular diagnosis of fusions to 
expect is necessary, and thus, it is also not required prior sequence-specific amplification 
of particular fusion transcripts (163). This approach could potentially lead to the 
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identification of both fusion transcripts already known and hypothetical novel fusion 
transcripts not yet described in the particular type of tumour being studied. 
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 Neoplasms frequently present structural chromosomal aberrations that can lead to 
change in the level of expression of a protein or to the expression of an aberrant chimeric 
protein. 
 It was demonstrated that thyroid follicular epithelial cells are more likely to use the 
mechanism of DNA repair than to induce apoptosis in case of DNA damage, increasing 
the likelihood for formation of fusion genes through chromosomal rearrangements (164), 
as occurred in post-Chernobyl thyroid cancers. 
 As aforementioned, the identification in thyroid tumours with the RET/PTC and 
PAX8-PPARG fusion genes (37, 53), raised the follicular-cell derived thyroid tumours as 
an exceptional and paradigmatic example of carcinomas presenting rearrangements that 
have mutations and “clonal” chromosomal translocations specifically associated with 
morphologic phenotypes (37-40). However, a considerable percentage of thyroid tumours 
(40%) still remain without any identified molecular alteration (165). Also, the prognostic 
value of the known molecular alterations in thyroid cancer is doubtful. 
 The ability to detect fusion genes can be relevant for a correct diagnosis and for 
therapy. The absence of biomarkers with a clear prognostic value in thyroid cancer and 
the particular susceptibility of the thyroid follicular epithelial cells to the formation of fusion 
genes along tumour development, places the thyroid tumours as a good model to screen 
fusion genes not yet described in thyroid pathology. 
 The doctoral thesis is divided in two parts: in Part I our objective was to clarify the 
role of already identified chromosomal rearrangements in thyroid epithelial tumours, and 
in Part II we aimed to detected fusion genes in thyroid tumours by a custom designed 
oligo microarray approach. The specific goals of each part of the doctoral thesis are 
described below. 
 
Part I. To clarify the role of chromosomal rearrangements in thyroid epithelial tumours: 
 
a) To characterize PTCs composed by two distinct patterns of growth - papillary and 
follicular, evaluating the presence of PAX8-PPARG and RET/PTC rearrangements in the 
different components; 
2 Aims 
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b) To compare the clinicopathological features and genetic alterations between 
multinodular PTC (MNPTC) and single nodule PTC (SNPTC), with focus in the presence 
of chromosomal rearrangements; 
c) To clarify the genotype-phenotype signature of FHCTs, evaluating the presence of 
PAX8-PPARG and RET/PTC rearrangements; 
d) To screen the presence of PAX8-PPARG and RET/PTC chromosomal rearrangements 
in rare and genetically uncharacterized cases of thyroid tumours. 
 
Part II. To identify existing and novel fusion genes in thyroid tumours using a custom 
designed oligo microarray. 
 Only few studies have used oligo microarrays targeting junction sequences to 
detect fusion transcripts (159-162). The use of the largest and most comprehensive such 
array design to date could lead to the identification of both fusion transcripts already 
known and novel fusion transcripts not yet described in thyroid tumours. 
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 Methods used in the different studies are briefly described in this section. The 
approaches followed for each study and detailed methodologies are indicated in the 
papers belonging to this thesis (Appendix). 
 
Biological samples 
 The biological samples included in the different studies are described in detail in 
the papers (Appendix). 
 Briefly, formalin-fixed and paraffin-embedded (FFPE) thyroid tumours and frozen 
tumour tissues were obtained from São João Hospital Center, Medical Faculty of Porto 
(Porto, Portugal), from University Medical Centre Groningen, University of Groningen 
(Groningen, The Netherlands), from Oslo University Hospital, Norwegian Radium Hospital 
(Oslo, Norway). Clinicopathological data was obtained from the files of the different 
institutions. The procedures were in accordance with the National ethical rules (DIÁRIO 
DA REPÚBLICA — I SÉRIE-A. N.o 18 — Lei nº12/2005 de 26 de Janeiro de 2005). The 
histology of all tumour samples was revised by experienced pathologists and the final 
classification was made according to the World Health Organization (WHO) criteria (3). 
 
Fluorescent in situ hybridization (FISH) 
 For the detection of RET/PTC and PAX8-PPARG rearrangements, FISH was 
performed on isolated nuclei extracted from 50 µm sections of FFPE thyroid tumour 
tissues. The isolation of nuclei from FFPE tissue and FISH were performed following the 
procedure described by Marques et al. (121). 
 RET/PTC rearrangements detection was investigated with a DNA probe generated 
from three yeast artificial chromosome clones (313F4, 214H10, 344H4) covering the RET 
locus (kindly provided by Professor Horst Zitzelsberger); probe hybridization was 
performed as described (166). BAC probes for PPARG (RPCI 1130 G23, BAC PAC 
Resources, Children's Hospital Oakland Research Institute, Oakland, California, USA) and 
PAX8 (RPCI 1165 I12, BAC PAC Resources) were used (121). FISH signals were 
analyzed and recorded with a CytoVision System (Applied Imaging, New Castle, UK). 
3 Material and Methods 
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 To establish the cut-off level for RET/PTC rearrangements, FISH was also 
performed on 10 normal thyroid specimens, obtained from the tissue bank of IPATIMUP. 
The average percentage of RET/PTC rearrangements in nuclei extracted from the control 
thyroid specimens was 3.35% (range 2.26-4.27%). Following Unger et al. (166), a value of 
(3 ) was used for calculation of the cut-off value. In the presence of ≥10% rearranged 
nuclei, we considered the case to be positive for RET/PTC rearrangements. FISH for 
PAX8-PPARG rearrangements was also performed on the 10 normal thyroid specimens 
referred above, to establish the positive cut-off level. The average percentage of PAX8-
PPARG rearrangements in nuclei extracted from the control thyroid specimens was 3.25% 
(range 1.50-5.37%). Using the same criteria referred above (3 ), we considered a case to 
be positive for PAX8-PPARG rearrangement when 10% of the nuclei were positive for the 
rearrangement. Thyroid cancer samples positive for RET/PTC1, RET/PTC3 and PAX8-
PPARG rearrangements by RT-PCR and cDNA sequencing were used as positive 
controls for FISH. 
 Further details about FISH approach can be found in the papers I-VI (Appendix). 
 
Mutation screening  
 Genomic DNA was extracted from 10-μm of FFPE tumour sections. Tumour areas 
were marked and manually dissected under microscopic observation. DNA extraction was 
performed with the Genomic DNA Purification Kit (Citomed, Lisbon, Portugal) according to 
the manufacturer’s protocol. For frozen tumours, genomic DNA was extracted using the 
Maxwell® 16 System (Promega, Madison, USA) according to the manufacturer’s protocol. 
 Polymerase chain reaction (PCR) followed by Sanger sequencing was used for 
mutation detection in the hotspot regions of HRAS (exon 2), NRAS (exon 2), BRAF (exon 
15), according to previously described procedures (40). 
 Further details about mutation screening can be found in the papers I-VII 
(Appendix). 
 
RT-PCR of RET/PTC1, RET/PTC3 and PAX8-PPARG rearrangements 
 Total RNA was extracted from frozen tumours using TRIzol® Reagent (ambion®, 
life technologies™, Califorinia, USA), according to the manufacturer’s protocol. cDNA was 
synthesized from 1 μg of RNA at 42º C for 60 min, using oligo (dT) primers and M-MuLV 
reverse transcriptase (Fermentas, Thermo Scientific, St. Leon-Rot, Germany). RT-PCR 
was performed following the procedure of Skotheim et al. (163). cDNA sequences of 
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RET/PTC1, RET/PTC3 and PAX8-PPARG were analysed as described previously (107, 
138). The housekeeping gene B-Actin was also amplified to control the cDNA integrity in 
the samples. 
 Further details about RT-PCR analysis of RET/PTC1, RET/PTC3 and PAX8-
PPARG rearrangements can be found in the papers I and VI (Appendix). 
 
Immunohistochemistry 
 Immunohistochemical studies were performed on 3m-thick paraffin sections using 
the avidin-biotin-peroxidase complex (ABC) and DAB – diaminobenzidine 
tetrahydrochloride- (Lab Vision Vector kit SK 4100 - Lab Vision Corporation, Fremont, 
USA) as chromogen, and the sections were counterstained with hematoxylin. 
 More details about immunochemistry, including antibodies, dilutions and suppliers 
are available in the papers III and IV (Appendix). 
 
Fusion gene microarray-based approach 
 The fusion gene microarray-based approach covers all possible chimeric 
combinations of exon-exon junction for each of the genes involved in the fusion gene and 
combines this with intragenic measurements within all exons up- and downstream of the 
fusion breakpoints (Fig. 4). 
 The greatest potential of this approach is the capacity to test in a single experiment 
all known fusion genes and some predicted new fusion genes involved in the 
tumorigenesis. Consequently, detection of fusion genes through the fusion gene oligo-
microarray approach can reveal fusion genes not yet reported in thyroid tumours which 
may represent an important alternative mechanism in the development of thyroid tumours. 
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Figure 4. : Microarray data for a positive fusion gene hit. A. Example of a fusion gene that has a crossing-
over event between sequences in intron 2 of gene A and intron 3 of gene B. B. If the genes A and B both have 
10 exons, the microarray will contain 10 × 10 = 100 oligos to cover all chimeric exon-to-exon junction 
combinations for this particular fusion gene. The A2-B4 oligo detects the chimeric breakpoint of the fusion 
transcript shown in (A). C. In true fusion events, the longitudinal profiles generated from intragenic oligos 
targeting each exon and exon-to-exon junction will provide independent confirmation. Adapted from Skotheim 
et al. (163). 
 
Fusion gene microarray analysis 
 The oligo design and data analysis of the fusion gene microarray were based on 
(163). Briefly, a database intended to cover all known fusion genes recorded until March 
2009 in Cancer Gene Census (167), TIC db (168), and the Mitelman database was 
compiled (169). In addition, by mining data for oncogenic fusion genes through scientific 
literature, 25 fusion genes reported in individual samples from deep sequencing studies 
[all fusion genes validated by reverse transcriptase-PCR (RT-PCR)] were included (170). 
Three oligo probes targeting internal sequences for every exon of all known fusion gene 
partners as well as chimeric junction oligos for every possible exon-exon junctions 
between all fusion gene pairs. In total, 28,056 unique intra-exonic oligos and 169,790 
unique chimeric exon-exon junction oligos for the 548 fusion genes were designed. Each 
chimeric oligo was included in triplicate, and a total set of 599,839 oligos were 
synthesised onto 3 x 720k HD2 microarrays (Roche NimbleGen, Inc., Madison, WI, USA). 
 Procedures for isolation of RNA, cDNA synthesis, labelling, and processing of the 
microarrays are described in detail in paper IX (Appendix). Fluorescently labelled cDNA 
from the samples were analysed using the Roche-NimbleGen custom microarray platform 
with a custom-designed set of oligos for detection of fusion genes; the oligo design and 
data analysis are described in detail in paper IX (Appendix) and in (163). The data was 
validated by RT-PCR and cDNA sequencing. 
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Data processing and analysis 
 Fluorescence intensity data were log2-transformed and for each feature, the 
measurements were median-centred by subtracting the median log2 value of that 
particular feature within the series of thyroid tumours. 
 The fusion detection algorithm (paper IX) included filters based on assumed exon-
level expression profiles of the fusion partners (gene A and B). Inspection of known 
positives controls of a sarcoma dataset revealed that the previous assumption did not hold 
the assumed exon-level expression profiles of the fusion partners (Løvf et al., 
unpublished). This indicates a need for a tissue optimized scoring algorithm. The actual 
changes to the original scoring algorithm (paper IX) include a change to the exon-level 
expression profile filter, an additional step of normalization to reduce half-binder effects for 
chimeric oligos and to enhance strong unique chimeric oligo scores. 
 Briefly, the normalization step for reduction of half-binder effects, i.e. when a part 
of a chimeric probe has such strong binding affinity that it produces strong signals even 
though only part A of the A+B probe binds, was implemented by iterating all rows and 
columns to rank all scores on that row/column. If more than 25% of the row/column 
probes (including the maximum scoring probe) have intensities ≥ 70% of the maximum 
score 1.5, or three or more probes have a score ≥ the chimeric threshold (3.0), all values 
on the row/column are set to 0. 
 Further, we observed that true positives often show a heatmap signature of one 
significantly warmer probe than all others. We implemented an enhancement for such 
“single-strong” probes by iterating all chimeric probe values (after removal of the half-
binder effects) for each possible fusion transcript, and if the maximum chimeric value is 
more than 40% higher than the second largest chimeric value, we adjusted the maximum 
chimeric value to its maximum value of 3.0. The factors used (25%, 70%, 1.5, 3.0 and 
40%) to define whether to perform normalization of half-binder effects or single probe 
enhancement was set after an iterative optimization process including interpretation of 
plots of score distributions for true and false positives. The general features of the 
algorithm and the factor-based use of threshold computation, instead of absolute values, 
indicate that the algorithm has not been over-fitted. 
 The remaining part of the scoring algorithm is according to the algorithm in paper 
IX (Appendix), and pseudocode for this is found in the paper VI (Appendix). 
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Experimental validation of candidate fusion genes 
 Plots for the top-ten candidate fusion genes were generated by data processing 
and bioinformatic analysis of the fusion gene microarray for each thyroid tumour sample, 
using the Diff-total automated scoring algorithm. By visual inspection and educated 
evaluation, we selected the most credible fusion plots for each sample for experimental 
validation. For nominated fusion genes, a forward primer was made to anneal in the last 
exon upstream of the breakpoint and a reverse primer in the first exon downstream of the 
breakpoint (Supplementary Table 1). The PCR using cDNA was performed with HotStar 
Taq DNA polymerase kit (Qiagen Co., Valencia, CA, USA), and initiated by denaturation 
at 95°C for 15 minutes, followed by 30 cycles of 30 seconds at 95°C (denaturation), 75 
seconds at 56-59°C (annealing), and 30 seconds at 72°C (elongation), before a final 
elongation step at 72°C for 6 minutes. The RT-PCR products were analysed by 2 % 
agarose gel electrophoresis. PCR reactions creating a visible band on the gel were 
sequenced directly (AB 3730 DNA analyser; Applied Biosystems by Life Technologies, 
Foster City, CA, USA) to further validate the presence of the fusion genes and their 
breakpoints. Because a negative RT-PCR reaction cannot be used as proof for the 
absence of the fusion gene, we sought to differentiate between non-functional PCR-
primers and absence of the candidate fusion gene. Thus, each primer from negative RT-
PCRs was tested by PCR amplification following the approach indicated in the Figure 5. A 
pair of positive primer testing results validated that both primers are functional and that the 
particular fusion gene breakpoint is not present in the sample in question. 
 
Figure 5. Schematic representation of the RT-PCR based strategy for validation of putative chimeric 
fusions nominated from the fusion gene microarray. In the example, a candidate fusion between an 
upstream Gene A and a downstream Gene B indicating a breakpoint between exons 8 and 2 of the two genes. 
RT-PCR is performed in the candidate samples with forward primer in Gene A’s exon 8 and reverse primer in 
Gene B’s exon 2. Upon negative results, we proceeded with primer testing to ensure that the primers are 
functional. For this, we designed for the Gene A, a reverse primer to the subsequent downstream exon, and 
for the gene B, a forward primer in the preceding upstream exon (test primers indicated in blue). Upon positive 
results of these intragenic PCRs, we concluded that the original fusion primers are working and the tested 
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samples are negative for the nominated fusion gene. Upon negative results, no conclusion could be drawn, 
and new primers were designed for the nominated fusion gene. 
 
Statistical analysis 
 Fisher's exact test, non-parametric Mann-Whitney U test and parametric 
independent samples t-test were used in the statistical analysis of the results with SPSS 
for Windows, V.19.0 (SPSS Inc., Chicago, IL, USA); values were considered significantly 
different when P < 0.05. 
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I – Role of chromosomal rearrangements in epithelial thyroid 
tumours 
a) Molecular heterogeneity disclosed by the comparison of papillary and 
follicular growth pattern areas of papillary thyroid carcinomas 
(Includes data from the original paper I in appendix, where further details may be found) 
 We investigated the genotype-phenotype signature of ten PTCs composed by two 
distinct patterns of growth - papillary and follicular. PTC patients presented a median age 
of 58y (32-85 years), eight patients were females and two patients were male and tumors 
had median size of 3.0 cm (1.6-5.6 cm). 
 Papillary- (n=11) and follicular-patterned (n=11) areas of ten PTCs (one case 
presented two distinct nodules) were evaluated for PAX8-PPARG and RET/PTC 
rearrangements and BRAF, NRAS and HRAS mutations (Table 1). No PAX8-PPARG 
rearrangements or RAS mutations were detected in the papillary-patterned areas. Eight 
(72%-8/11) papillary patterned areas were positives for RET/PTC rearrangements and six 
(54%-6/11) presented BRAFV600E mutation. In the follicular pattern areas PAX8-PPARG, 
RET/PTC rearrangements and NRAS mutation (p.Q61K) were detected in 36% (4/11), 
18% (2/11) and nine percent (1/11), respectively. No BRAF mutations were detected in 
follicular patterned areas of PTC. 
 By FISH approach, the percentage of tumoral cells positive for RET/PTC 
rearrangement (Fig. 6) was higher (and with marginal significance) in areas with papillary 
growth pattern (mean 20.5%) than in areas with follicular growth pattern (mean 11.9%) 
(p=0.056). Conversely, the percentage of tumoral cells positives for PAX8-PPARG 
rearrangements (Fig. 6) was significantly higher on follicular (16.2%) than in the papillary 
(5.1%) patterned areas (p=0.034). Curiously, in the two cases (cases 2, 3) positive for 
RET/PTC rearrangement in the two growth patterns, papillary and follicular areas, the 
percentage of tumoral cells with rearranged nuclei was similar in the two different 
morphologies (Fig. 6). Detection of RET/PTC1 in papillary and follicular areas of PTC 
case 2 and the detection of PAX8-PPARG rearrangements in follicular area of PTC case 9 
were confirmed by RT-PCR approach. 
4 Results 
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Table 1. Molecular alterations in dissected areas of papillary and follicular growth pattern of papillary 
thyroid carcinomas (PTCs) studied. 
Case 
number 
Growth 
Pattern 
Rearrangements Mutations 
RET/PTC PAX8-PPARG BRAF exon15 
NRAS 
exon2 
HRAS 
exon2 
1 
Papillary* Pos (21.8%) Neg (9.1%) V600E Neg Neg 
Follicular* Neg (9.8%) Pos (13.0%) Neg Neg Neg 
2 
Papillary* Pos (58.0%)1,2 Neg (2.0%)1 Neg Neg Neg 
Follicular* Pos (53.9%)1,2 Neg (5.9%)1 Neg Neg Neg 
3 
Papillary* Pos (19.2%) Neg (7.1%) Neg Neg Neg 
Follicular* Pos (15.8%) Neg (9.3%) Neg Neg Neg 
4 
Papillary* Neg (4.6%) Neg (5.7%) Neg Neg Neg 
Follicular* Neg (3.1%) Pos (15.1%) Neg Neg Neg 
5 
A 
Papillary* Pos (21.8%) Neg (3.4%) V600E Neg Neg 
Follicular* Neg (9.0%) Neg (5.5%) Neg Q61K Neg 
B 
Papillary Pos (25.3%) Neg (6.7%) V600E Neg Neg 
Follicular Neg (9.1%) Neg (5.7%) Neg Neg Neg 
6 
Papillary Pos (18.4%) Neg (4.5%) Neg Neg Neg 
Follicular Neg (9.5%) Pos (15.1%) Neg Neg Neg 
7 
Papillary Pos (24.6%) Neg (3.9%) V600E Neg Neg 
Follicular Neg (9.8%) Neg (5.0%) Neg Neg Neg 
8 
Papillary Pos (21.2%) Neg (4.8%) V600E Neg Neg 
Follicular Neg (1.1%) Neg (5.3%) Neg Neg Neg 
9 
Papillary Neg (3.1%)1 Neg (3.2%)1 Neg Neg Neg 
Follicular Neg (4.1%)1 Pos (93.6%)1,3 Neg Neg Neg 
10 
Papillary Neg (8.0%) Neg (5.6%) V600E Neg Neg 
Follicula Neg (6.0%) Neg( 4.3%) Neg Neg Neg 
Neg, negative; Pos, positive; *, papillary and follicular growth patterns were located in the same PTC nodule; 
1, result confirmed by RT-PCR; 2, breakpoint at the end of exon 1 (CCDC6), the breakpoint in RET is in exon 
12; 3- breakpoint at the end of exon 7, exon 8 and exon 9 (PAX8); the breakpoint in PPARG is in exon 1. 
 
 Papillary-patterned areas of PTCs were significantly associated with the presence 
of BRAF mutation (p.V600E) (p=0.012) and RET/PTC rearrangements (p=0.030); PAX8-
PPARG rearrangements and RAS mutations were exclusively detected in areas of PTC 
with follicular growth pattern. The coexistence of two molecular alterations - RET/PTC 
rearrangements and BRAF mutation (p.V600E), was significantly associated (p=0.035) 
with papillary-patterned areas (45%-5/11). 
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Figure 6. Distribution of cells with positive nuclei (%) for the RET/PTC and PAX8-PPARG 
rearrangements in the PTC areas of papillary and follicular growth pattern. The columns represent the 
frequency of positive cells detected by interphase fluorescence in situ hybridization (FISH). Horizontal dashed 
line represents the cut-off level established of 10%. *: papillary and follicular growth pattern areas in the same 
PTC nodule. 
 
b) Distinct prevalence of RET/PTC and PAX8-PPARG rearrangements among 
multinodular and single nodule papillary thyroid carcinomas 
(Unpublished data) 
 Twenty-six PTCs - nine (35%-9/26) multinodular PTCs (MNPTCs) (Table 2) and 17 
(65%-17/26) single nodule PTCs (SNPTCs) (Table 3), were investigated for the positivity 
for RET/PTC and PAX8-PPARG rearrangements and BRAF, NRAS and HRAS mutations. 
The genetic alterations and the clinicopathological features were compared between 
MNPTCs and SNPTCs. 
 The median age of the patients with MNPTC and SNPTC were 63 y (32-85 years) 
and 47 y (24-76 years), respectively. The gender ratio (female:male) of the patients was 
3.5:1 for MNPTCs and 16:1 for SNPTCs. The MNPTCs were significantly larger (3.5±0.49 
cm) than the SNPTCs (2.0±0.15 cm) (p=0.004) (Table 4). No other clinicopathological 
differences were found between MNPTCs and SNPTCs. 
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Table 2. Molecular alterations in dissected areas of multinodular papillary thyroid carcincomas 
(MNPTCs). 
PTC case Growth pattern 
Rearrangements Mutations 
RET/PTC PAX8-PPARG 
BRAF 
exon15 
NRAS 
exon2 
HRAS 
exon2 
1m 
Papillary* Pos (21.8%) Neg (9.1%) V600E Neg Neg 
Follicular* Neg (9.8%) Pos (13.0%) Neg Neg Neg 
2m 
A 
Papillary* Pos (21.8%) Neg (3.4%) V600E Neg Neg 
Follicular* Neg (9.0%) Neg (5.5%) Neg Q61K Neg 
B 
Papillary Pos (25.3%) Neg (6.7%) V600E Neg Neg 
Follicular Neg (9.1%) Neg (5.7%) Neg Neg Neg 
3m 
Papillary Pos (24.6%) Neg (3.9%) V600E Neg Neg 
Follicular Neg (9.8%) Neg (5.0%) Neg Neg Neg 
4m 
Papillary Pos (21.2%) Neg (4.8%) V600E Neg Neg 
Follicular Neg (1.1%) Neg (5.3%) Neg Neg Neg 
5m 
Papillary* Pos (58.0%) Neg (2.0%) Neg Neg Neg 
Follicular* Pos (53.9%) Neg (5.9%) Neg Neg Neg 
6m 
Papillary* Pos (19.2%) Neg (7.1%) Neg Neg Neg 
Follicular* Pos (15.8%) Neg (9.3%) Neg Neg Neg 
7m 
Papillary Neg (8.0%) Neg (5.6%) V600E Neg Neg 
Follicular Neg (6.0%) Neg( 4.3%) Neg Neg Neg 
8m 
Papillary Neg (3.1%) Neg (3.2%) Neg Neg Neg 
Follicular Neg (4.1%) Pos (93.6%) Neg Neg Neg 
9m 
Papillary Pos (18.4%) Neg (4.5%) Neg Neg Neg 
Follicular Neg (9.5%) Pos (15.1%) Neg Neg Neg 
PTC, papillary thyroid carcinoma; Pos, positive; Neg, negative; ND, not determined; Met, metastasis. 
*- papillary and follicular growth patterns were located in the same PTC nodule. 
 
 RET/PTC rearrangement was detected in one (6%-1/17) and in seven (78%-7/9) of 
SNPTCs and MNPTCs, respectively. It was observed in MNPTCs that positivity for 
RET/PTC rearrangement appeared both in papillary and follicular growth pattern areas of 
two (22%-2/9) cases (Table 2). PAX8-PPARG rearrangement was detected in one (6%-
1/17) SNPTC, restricted to the follicular growth pattern area (Table 3). PAX8-PPARG 
rearrangement was also detected in three (33%-3/9) MNPTCs, in which this 
rearrangement was also restricted to the follicular growth pattern areas (Table 2). BRAF 
mutation (p.V600E) was detected in eleven (65%-11/17) SNPTCs and in five (56%-5/9) 
MNPTCs, while RAS mutations were detected in two (12%-2/17) SNPTCs (NRAS 
p.Q61R) and in one (11%-1/9) MNPTC (NRAS p.Q61K). In MNPTCs, it was possible to 
verify that BRAF mutations were restricted to the papillary growth pattern areas and RAS 
mutations were restricted to the follicular growth pattern areas (Table 2). 
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Table 3. Molecular alterations in dissected areas of single nodule papillary thyroid carcinomas 
(SNPTCs). 
PTC case Growth pattern 
Rearrangements Mutations 
RET/PTC PAX8-PPARG 
BRAF 
exon 15 
NRAS 
exon 2 
HRAS 
exon 2 
1s Papillary Neg Neg V600E Neg Neg 
2s Papillary Neg Neg V600E Neg Neg 
3s Papillary Neg Neg V600E Neg Neg 
4s Papillary Neg Neg V600E Neg Neg 
5s Papillary Neg (7.3%) Neg (4.3%) V600E Neg Neg 
6s Papillary Neg (5.6%) Neg (4.8%) V600E Neg Neg 
7s Papillary Neg Neg V600E Neg Neg 
8s Papillary Neg Neg V600E Neg Neg 
9s Papillary Neg Neg V600E Neg Neg 
10s Papillary Neg Neg V600E Neg Neg 
11s Papillary/follicular Neg Neg V600E Neg Neg 
12s Papillary/follicular Neg Neg Neg Q61R Neg 
13s Papillary/follicular Neg Neg Neg Q61R Neg 
14s Papillary Neg (2.0%) Neg (2.9%) Neg Neg Neg 
15s Papillary/follicular Neg (5.7%) Neg (4.11%) Neg Neg Neg 
16s Papillary Pos Neg Neg Neg Neg 
17s 
Papillary* Neg (4.6%) Neg (5.7%) Neg Neg Neg 
Follicular* Neg (3.1%) Pos (15.1%) Neg Neg Neg 
PTC, papillary thyroid carcinoma; Pos, positive; Neg, negative; ND, not determined; Met, metastasis. 
* - papillary and follicular growth patterns were located in the same PTC nodule. 
 
 Detection of RET/PTC rearrangements was significantly more frequent in MNPTCs 
than in SNPTCs (p<0.001) (Table 4). PAX8/PPARG rearrangements were also more 
frequently detected in MNPTCs (33%) than in SNPTCs (6%), although not reaching 
significance (p=0.104). BRAF and RAS mutations were detected in SNPTCs at similar 
frequencies that were found in MNPTC. Multiple genetic alterations were only found in 
MNPTCs (44%-4/9) (p=0.008) (Table 4) – consisting in presence of RET/PTC 
rearrangement and BRAFV600E mutation in papillary growth pattern areas. 
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Table 4. Comparison of clinicopathological and molecular features between single nodule papillary 
thyroid carcinomas (SNPTCs) and multinodular papillary thyroid carcinomas (MNPTCs). 
 SNPTC (n=17) MNPTC (n=9) p value 
Age (average) 44.9 57.2 p=0.092 
Gender 16F:1M 7F:2M p=0.268 
Mean tumor size (cm, average) 2.0 3.5 p=0.004 
Lymph node metastasis 17.6% (3/17) 55.6% (5/9) p=0.078 
Vascular invasion 17.6% (3/17) 55.6% (5/9) p=0.078 
Lymphocytic thyroiditis 58.8% (10/17) 22.2% (2/9) p=0.110 
Multinodular goiter 0% (0/17) 11.1% (1/9) p=0.346 
Presence of Capsule 70.6% (12/17) 55.6% (5/9) p=0.667 
RET/PTC rearrangements 5.9% (1/17) 77.8% (7/9) p=0.000 
PAX8-PPARG rearrangements 5.9% (1/17) 33.3% (3/9) p=0.104 
BRAF mutations 64.7% (11/17) 55.6% (5/9) p=0.692 
RAS mutations 11.8% (2/17) 11.1% (1/9) p=1.000 
Two or more molecular alterations 0%(0/17) 44.4% (4/9) p=0.008 
Statistical differences are considered as significant when p<0.05; F, female; M, male; NS, non-significant. S, 
significant;  
 
c) RET/PTC rearrangement is prevalent in follicular Hürthle cell carcinomas 
(Includes data from the original paper II in appendix, where further details may be found) 
 In an attempt to clarify the genetic alterations involved in FHCT and to see if there 
is any relationship between the presence of molecular alterations and the 
clinicopathological features of the tumours, we investigated 20 FHCT – 3 FHCA and 17 
FHCC, for RET/PTC and PAX8/PPARG rearrangements and BRAF, HRAS and NRAS 
mutations. 
 Of the 20 FHCT, RET/PTC rearrangement was properly studied in 19 cases (Fig. 
7A). One FHCA (33%-1/3) and six FHCC (38%-6/16) were RET/PTC positive. From the 
18 cases successfully analysed for PAX8/PPARG rearrangement (Fig. 7B), four FHCC 
(27%-4/15) presented the rearrangement. Additionally, one NRAS mutation (p.Q61K) was 
found in one FHCC (6%-1/17) and no mutations were detected in BRAF or HRAS genes 
in any of the 20 cases of FHCT. One FHCC with solid/microfollicular growth pattern 
presented two genetic alterations, RET/PTC and PAX8/PPARG rearrangement. 
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Figure 7. A. Representative result obtained in the FISH analysis for RET/PTC rearrangement. Green 
dots are the YAC probes for 344H4, red dots are YAC probes for 313F4 and 214H10; the nuclei are stained 
with DAPI. Nuclei in which the red and green dots were separated were scored as positive for fusion gene 
(arrow) (1000X). B. Representative result obtained in the FISH analysis for PAX8-PPARG 
rearrangement. Green dots are the BAC probes for PPARG, red dots are BAC probes for PAX8; the nuclei 
are stained with DAPI. Nuclei in which the red and green dots were fused or touching were scored as positive 
for fusion gene (arrow) (1000X). Adapted from de Vries & Celestino et al. (171). 
 
 The presence of RET/PTC rearrangements was significantly associated with a 
solid pattern of growth (Fig. 8B) in FHCC (p = 0.01). At variance, 3 out of the 4 FHCC 
positive for PAX8/PPARG rearrangement (75%) showed a follicular growth pattern (Fig. 
8A), but this latter finding does not reach the threshold of statistical significance. 
 
Figure 8. A. FHCC with follicular growth pattern (200X). B. FHCC with solid growth pattern (200X HE). 
Adapted from de Vries & Celestino et al. (171). 
 
 No further significant differences were observed between cases with and without 
any of the genetic alterations and the clinicopathological features under observation. 
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d) PAX8-PPARG and RET/PTC chromosomal rearrangements in rare and 
genetically uncharacterized cases of epithelial thyroid tumours 
d.1) Struma Ovarii as an unequivocal example of specific molecular alterations 
associated with specific thyroid tumour type 
(Includes data from the original paper III in appendix, where further details may be found) 
 A right ovarian cyst from a 38-year-old female was studied macroscopically, 
histologically and immunocytochemically leading to the tentative diagnosis of FVPTC.  
 The histological examination of hematoxylin and eosin (HE) stained sections 
showed a tumour with an almost exclusive follicular growth pattern with the typical nuclei 
of PTCs (Fig. 9A). Focal areas with papillary morphology were also observed. The tumour 
cells showed positive immunoexpression for thyroid transcription factor-1 (TTF-1) and 
thyroglobulin, and they were diffuse and intensively positive for Galectin-3 and HBME-1 
and focally positive for Cytokeratin 19. No immunoreactivity was detected for 
chromogranin, synaptophysin and progesterone receptor. A diagnosis of MSO with 
FVPTC phenotype was made. 
 
Figure 9. A. An area of the tumour with papillary carcinoma-like nuclei in follicular structures (400x 
HE). B. Mutation of NRAS gene in codon 61. CAA > CGA change that leads to a substitution of glutamine 
by an arginine (Q61R). C. Representative result obtained in the FISH analysis for PAX8-PPARG 
rearrangement. Green dots are the BAC probes for PPARG, red dots are BAC probes for PAX8; the nuclei is 
stained with DAPI. Nuclei in which the 2 probes were fused or touching were scored as positive for fusion 
gene (arrow) (1000X). Adapted from Celestino et al. (172). 
 
 No mutations were detected in the BRAF (exon 15) and HRAS (exon 2). NRAS 
mutation was found in exon 2 (p.Q61R; Fig. 9B). A PAX8-PPARG rearrangement was 
detected in 16% of 200 analysed nuclei (Fig. 9C).  
 
d.2) Follicular thyroid carcinoma with an unusual glomeruloid pattern of growth 
was positive for PAX8-PPARG rearrangement 
(Includes data from the original paper IV in attachment, where further details may be found) 
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 We presented the first report of a peculiar FTC with an glomeruloid pattern of 
growth (Fig. 10A) in a 56-year-old woman. The tumour, with 5 cm, was widely infiltrating 
and angioinvasive, exhibiting a peculiar architectural growth pattern – glomeruloid 
morphology. Nuclei were round to oval, with evenly distributed, slightly coarse chromatin. 
 Immunohistochemical studies showed tumour cells were positive for thyroid 
transcription factor- 1, thyroperoxidase, thyroglobulin, cytokeratin 18, Hector Battifora 
mesothelial cell, and vimentin. Scattered cells positive for S100, Wilms tumor 1 (WT1), 
and cytokeratins AE1/AE3 were found, with no reaction detected for cytokeratins 34βE12, 
5/6, 7, 19, or 20. 
 
Figure 10. Glomeruloid variant of follicular thyroid carcinoma. A. Peculiar growth pattern with 
glomeruloid features (200x HE). B. Representative result obtained in the FISH analysis for PPARG and 
PAX8. Green dots are the BAC probes for PPARG, red dots are BAC probes for PAX8; the nucleus is stained 
with DAPI. Nuclei in which the 2 probes were fused or touching were scored as positive for fusion gene 
(arrow). Adapted from Cameselle-Teijeiro et al. (169). 
 
 The study of genetic alterations revealed positivity for PAX8-PPARG 
rearrangement (Fig. 10B), in 20% of the tumour cells. Additionally, a NRAS mutation 
(p.Q61R) was found. No mutations were found for APC or BRAF genes, nor RET/PTC 
rearrangements were detected.  
 Four years later, we had access to a sample from a relapse of the FTC, again with 
the glomeruloid growth pattern present in the primitive tumour (unpublished data). Genetic 
study revealed, as in the primitive lesion, positivity of the tumour cells for NRAS mutation 
(p.Q61R), and the presence of the PAX8-PPARG rearrangement in 12% of the tumour 
cells . 
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d.3) PAX8-PPARG rearrangement mosaicism identified in a patient with an 
autonomous functioning follicular thyroid carcinoma 
(Includes data from the original paper V in, where further details may be found) 
 We report here a 55 years-old Spanish woman presenting hyperthyroidism caused 
by an autonomously hyperfunctioning FTC with angioinvasive behaviour. The tumour 
harboured a somatic TSHR mutation (p.M453T) leading to a higher basal cAMP activity 
(173). No TSHR gene mutation was found in DNA samples from patient's normal thyroid 
tissue specimen or from peripheral blood lymphocytes (PBLs). No RAS or BRAF 
mutations were found in the FTC nor in normal thyroid tissue. 
 A  PAX8-PPARG rearrangement was found in the tumour DNA by RT-PCR and 
confirmed by direct sequencing. Surprisingly, PAX8-PPARG rearrangement was also 
present in the DNA from patient's normal thyroid tissue, PBLs, and uterine leiomyoma 
(surgically removed, 15 years before the date of the study). 
 FISH analysis further confirmed the presence of the PAX8-PPARG rearrangement 
in all the patient’s analysed tissue samples - FTC, adjacent normal thyroid tissue, PBL, 
and uterine leiomyoma (Fig. 11). FISH showed a similar percentage of PAX8-PPARG 
rearrangement in nuclei extracted from the patient tumoral and normal thyroid tissue and 
in PBL (16.5, 16.4, and 14% respectively). No quantification was possible in the 
leiomyoma tissue due to the low quantity of nuclei obtained. No PAX8-PPARG 
rearrangement was detected in PBL samples, either from the patient’s daughter or from 
her two siblings when screened by RT-PCR and by FISH. 
 
Figure 11. Representative results obtained in the FISH analysis for PPARG and PAX8. Green dots are 
the BAC probes for PPARG, red dots are BAC probes for PAX8, and the nuclei are stained with DAPI. Nuclei 
in which the two probes were fused or touching were scored as positive for the fusion gene. A. Nucleus 
extracted from adjacent normal thyroid tissue positive for the PAX8-PPARG rearrangement. B. Nucleus 
extracted from tumoral tissue positive for the PAX8-PPARG rearrangement. C. Nuclei extracted from adjacent 
normal thyroid tissue negative for the PAX8-PPARG rearrangement. D. Nuclei extracted from PBL positive for 
the PAX8-PPARG rearrangement. Adapted from Lado-Abeal et al. (174). 
 
 No genetic material was available from the patient's parents, making it impossible 
for us to test for PAX8-PPARG rearrangement and elucidate if we were facing a 
hereditary case or a de-novo case. 
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II - Screening of 548 known and putative fusion genes in epithelial 
thyroid tumours through a custom oligo microarray-based 
approach analysis 
(Includes data from the original paper VI in, where further details may be found) 
 A new oligo microarray-based approach for simultaneous analysis of all known and 
predicted fusion gene variants has been developed (163, 170). This approach covers all 
possible chimeric combinations of exon-exon junction for each of the genes known to be 
involved in  fusions and combines this with intragenic measurements of exons up- and 
downstream of the fusion breakpoints. 
 We did a comprehensive screen for 548 known and putative fusion genes in 27 
samples of thyroid tumours – eight FTAs, seven FTCs, five FVPTCs, six cPTC and one 
oncPTC, using the aforementioned custom designed oligo microarray. 
 Additionally, the thyroid neoplasm were further characterized for the known 
molecular alterations in thyroid tumours, namely RET/PTC1, RET/PTC3 and PAX8-
PPARG rearrangements by RT-PCR and cDNA sequencing, and NRAS, HRAS and 
BRAF mutations (40, 107, 138).  
 Validation of fusion gene microarray analysis was done by using as positive 
controls two cPTC cases (8PT and 11PT) and one thyroid cancer cell line (TPC-1) all 
presenting the RET/PTC1 rearrangement as validated by RT-PCR and cDNA sequencing 
(Fig. 12D) 
 The automated scoring algorithm identified the correct fusion gene in the top 
scoring gene pair (rank number 1 out of 548 possible fusion genes) in the TPC-1 thyroid 
cancer cell line (Fig. 12A) and in one cPTC case (11PT; Fig. 12B) (rank number 4 out of 
548 possible fusion genes). In the other cPTC positive control (8PT), the RET/PTC1 
rearrangement was ranked 42nd of 548 tested fusion genes, although a correct fusion like 
expression pattern was also seen for this sample (Fig. 12C). For all three positive 
samples, the RET/PTC1 fusion has a breakpoint between exon 1 (transcript reference 
ENST00000395341) of the CCDC6 upstream gene and exon 12 (transcript reference 
ENST00000355710) of the RET downstream gene. Quantification by FISH (Fig. 12E, 
Table 5) showed that 94% of cell nuclei of the TPC-1 thyroid cancer cell line and 50% of 
tumour cells of PTC case 11PT were positive for RET/PTC rearrangements. In PTC case 
8PT, 25% of tumour cell nuclei showed RET/PTC rearrangements. 
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Figure 12. CCDC6-RET (alias RET/PTC1) fusion gene as seen from the fusion gene microarray data in 
the three positive controls. Plots from fusion gene microarray data are shown for A) the TPC-1 thyroid 
cancer cell line, B) the cPTC sample 11PT, and C) the cPTC sample 8PT. For each of the three samples, 
intensity heatmap of chimeric oligos covering all possible exon-exon junction combinations (left) and 
corresponding intragenic expression profiles with oligos targeting within all exons of the two fusion partners 
(right) are shown. Blue and red colours in the intragenic expression profiles represent the two sides of the 
nominated chimeric transcripts. D) Sequence of RT-PCR product of the 11PT sample. E) Representative 
result obtained in the FISH analysis for RET/PTC rearrangement of the 11PT sample. Green signals derive 
from the YAC probes for 344H4, red signals derive from the YAC probes for 313F4 and 214H10; the nuclei 
are counter-stained with DAPI. Nuclei in which the red and green signals were separated were scored as 
positive for the fusion gene (1000X). Adapted from Celestino et al. (175). 
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Table 5. Thyroid samples with known fusion genes, based on the FISH analyses. 
Sample Known fusion gene Fusion score Rank (diff-total) Rearranged nuclei (%)FISH 
TPC-1 cell line CCDC6-RET (RET/PTC1) 5.92 1 94.0 
2PT PAX8-PPARG 5.31 1 93.6 
11PT CCDC6-RET (RET/PTC1) 3.85 4 49.6 
8PT CCDC6-RET (RET/PTC1) 4.35 42 25.1 
5PT NCOA4-RET (RET/PTC3) 1.36 281 19.2 
 
 The PAX8-PPARG fusion gene was detected in one FVPTC (2PT), and it was top-
ranked among all of the 548 tested fusion genes (Fig. 13A). The fusion occurs between 
exon 6 (transcript reference ENST00000351165) of the PAX8 upstream gene and exon 3 
(transcript reference ENST00000397023) of the PPARG downstream gene. Presence of 
the fusion transcript and the correct breakpoint were validated by RT-PCR and cDNA 
sequencing analysis (Fig. 13B). Quantification by FISH of rearranged nuclei (Fig. 13C, 
Table 5) showed that 94% of cell nuclei of case 2PT are positive for the PAX8-PPARG 
rearrangement. 
 
Figure 13. PAX8-PPARG fusion gene detected in a FVPTC (2PT). A) Intensity heatmap of chimeric oligos 
covering all possible exon-exon junction combinations (left side); corresponding intragenic expression profiles 
with oligos targeting within all exons of upstream (PAX8) and downstream (PPARG) fusion gene partners 
(right side). Blue and red colours indicate the two sides of the predicted fusion breakpoint. B) Sequence of the 
RT-PCR product. C) Representative result obtained in the FISH analysis for PAX8-PPARG rearrangement. 
Green signals derive from the BAC probes targeting PPARG, red signals derive from the BAC probes 
targeting PAX8; the nuclei are counter-stained with DAPI. Nuclei in which the red and green signals were 
fused or touching were scored as positive for the fusion gene (1000X). Adapted from Celestino et al. (175). 
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 Additionally, we detected the RET/PTC3 rearrangement in one FVPTC (5PT) by 
RT-PCR and confirmed by cDNA sequencing analysis (Fig. 14B). The RET/PTC3 fusion 
has a breakpoint sequence between exon 3 (transcript reference ENST00000340589) of 
the NCOA4 upstream gene and exon 12 (transcript reference ENST00000340058) of the 
RET downstream gene. This fusion gene was not detected from the automated scoring of 
the fusion gene microarray data (ranked 281 out of 548 possible fusion genes). However, 
visual inspection of the fusion gene microarray plot reveals a weak fusion-like pattern, 
matching the correct breakpoints (Fig. 14A). Quantification by FISH of rearranged nuclei 
(Fig. 14C; Table 5) showed that 19% of cell nuclei of FVPTC case 5PT are positive for 
RET/PTC rearrangements. 
 
Figure 14. RET/PTC3 (NCOA4-RET) fusion gene detected in a FVPTC (5PT) case. A) Intensity heatmap of 
chimeric oligos covering all possible exon-exon junction combinations (left side); corresponding intragenic 
expression profiles with oligos targeting within all exons of upstream (NCOA4) and downstream (RET) fusion 
gene partners (right side). Blue and red colours indicated the two sides of the predicted fusion breakpoint. B) 
Sequence of the RT-PCR product. C) Representative result obtained in the FISH analysis for RET/PTC 
rearrangement. Green signals derived from the YAC probes for 344H4, red signals derive from the YAC 
probes for 313F4 and 214H10; the nuclei are counter-stained with DAPI. Nuclei in which the red and green 
signals were separated were scored as positive for the fusion gene (1000X). Adapted from Celestino et al. 
(175). 
 
 For each sample analysed on the fusion gene microarray, including the positive 
controls, the top-ten highest fusion scores were selected for visual inspection of heatmap 
plots. Forty nine different candidate fusion genes were again selected for experimental 
testing by RT-PCR to explore the presence of known fusion genes which may be novel to 
thyroid cancer (Table 6). No additional fusion genes were confirmed. 
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Table 6. Nominated fusion genes and corresponding thyroid tumour samples tested. 
Candidate fusion gene Sample(s) tested Candidate fusion gene Sample(s) tested
BCR-ABL1 17NT  MLL-FNBP1 27NT, 28NT 
BCR-FGFR1 7NT, 17NT  MLL-RARA 4NT 
BCR-PDGFRA 7NT, 13NT  MLL-SARNP 6NT 
BCR-SET 21NT, 29NT  MYH9-ALK 5PT 
CANT1-ETV1 27NT, 29NT  NACA-BCL6 11PT 
CEP110-FGFR1 5NT, 6NT, 7NT, 9NT  NCOA4-RET TPC-1 
CLTC-TFE3 4NT  NPM1-ALK 24NT 
COL1A1-PDGFB 9NT  NPM1-RARA 28NT, 8PT 
DEK-NUP214 2PT  NUMA1-RARA 26NT, 8PT 
ELF2-MLL 25NT  ODZ4-NRG1 6NT 
FCHSD1-BRAF 1NT, 5NT, 6NT, 3PT  PAX8-PPARG 5NT, 20NT, 21NT, 2PT 
FOXP1-ETV1 4NT  PDE4DIP-PDGFRB TPC-1 
FUS-ERG 29NT, 8PT  PML-RARA 26NT 
GAPDH-BCL6 25NT, 28NT  POU2AF1-BCL6 8PT 
HCK-C20orf112 1NT, 4PT  RPS6KB1-TMEM49 1NT 
HMGA1-LAMA4 TPC-1  SS18L1-SSX1 12NT, 13NT, 17NT, 4PT 
HNRPA2B1-ETV1 25NT, 27NT, 28NT, 8PT  SS18-SSX7 12NT 
HSP90AA2-BCL6 1PT  STAT5B-RARA 26NT, 27NT 
HSP90AB1-BCL6 28NT  TAF1-CHN1 1NT, 7NT 
KIAA1549-BRAF 20NT  TMPRSS2-ERG TPC-1 
KTN1-RET 12NT  TPM3-ALK 24NT 
LCP1-BCL6 24NT, 25NT, 28NT, 11PT  TRIM24-RARA 5NT 
MIPLO1-DGKB 1PT, 4NT  ZBTB16-RARA 27NT, 29NT 
MIPLO1-ETV1 1PT, 4NT  ZMIZ1-ABL1 7NT, 17NT, 20NT, 5PT 
MLL-BCL9L 3PT    
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 RET/PTC rearrangements are largely associated to PTC (53) and PAX8-PPARG 
rearrangements are associated to epithelial thyroid tumours with a follicular growth pattern 
- FTA, FTC and FVPTC (37, 40, 107, 111). RAS mutations are also more frequent in 
lesions that have a follicular architecture (2, 40, 176). BRAF mutation (p.V600E) is the 
most prevalent mutation present in PTC (2, 130), and it is closely associated to papillary 
or mixed papillary/follicular architecture of PTC (131). Despite acknowledging this close 
genotype-phenotype signature, it remains unclear if this association remains in PTCs 
composed by mixed growth pattern – papillary and follicular architecture.  
 We studied ten PTCs composed by these two papillary and follicular morphologies 
(paper I). BRAF mutation (p.V600E) was significantly restricted to PTC areas with 
papillary growth pattern. This heterogeneous distribution of BRAF mutation in PTC with 
mixed morphology contrast with a previous report showing an identical mutational profile 
of BRAF mutation (p.V600E) for distinct areas of papillary and follicular growth patterns 
from the same tumour nodule (177). Additionally, PAX8-PPARG rearrangements and RAS 
mutations were exclusively detected in areas with a follicular growth pattern, similarly to 
other reported in the literature (2, 37, 40, 107, 111, 176). RET/PTC rearrangements were 
significantly associated with papillary pattern areas of PTC. However, RET/PTC 
rearrangement was detected in both morphologies (papillary and follicular) in two PTCs. 
This result suggests that the papillary and follicular areas of these two PTC cases can 
have the same clonal origin. 
 The co-expression of two molecular alterations - RET/PTC rearrangements and 
BRAF mutation, in the same nodule was significantly associated with papillary 
morphology. In a previous report, RET/PTC rearrangements and BRAF mutations appear 
as alternative events in the etiopathogenesis of the PTC (123). However, subsequently, 
other authors found that the occurrence of RET/PTC rearrangements and BRAF 
mutations is not always mutually exclusive (66, 124, 126-129). In a study using a 
melanoma model it was showed that BRAF and NRAS mutations can coexist in the same 
tumour, however the authors also revealed that these molecular alterations are mutually 
exclusive at the single-cell level (178). In our series, tumoral cells positives for RET/PTC 
rearrangements represent a subpopulation (20%) of the papillary-patterned areas of the 
mixed PTCs. Then, it is compatible with the possible coexistence in the same tumour of 
other subclones, containing tumour cells carrying BRAF mutation (p.V600E) - intratumoral 
5 Discussion and Conclusions 
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genetic heterogeneity. Our results fits with previous report showing that the percentage of 
tumour cells with RET/PTC rearrangements was rather low in PTC (179). Furthermore, 
chromosomal rearrangements involving RET gene were already found in a small 
population of others cancer types (180-184), suggesting that this rearrangements could 
represent a “passenger mutation”, being present in a subclone of the tumour (179). 
Recently, it was demonstrated that BRAF mutation (p.V600E) in PTC is a subclonal event, 
reinforcing the idea of the intratumoral genetic heterogeneity of the PTCs (125). 
Altogether, our results in mixed nodules of PTC reinforce the close phenotype-genotype 
association in PTCs. 
 PTC is frequently multinodular and the most common variant is the cPTC (3). It 
was shown that the presence of RET/PTC rearrangements in MNPTC differ between 
tumour nodules of the same patient (70). We hypothesized that the clinicopathological and 
genetic features of the MNPTCs differ from SNPTCs. We investigated a series of nine 
MNPTCs and 17 SNPTCs (unpublished data), and we also verified in this setting that 
PAX8-PPARG rearrangements and RAS mutations were restricted to the follicular pattern 
areas of MNPTCs and SNPTCs, in accordance with the previous findings (2, 37, 40, 107, 
111, 176). BRAF mutation (p.V600E) was associated to the papillary or mixed 
(papillary/follicular) growth pattern of MNPTCs and SNPTCs, as described before (131, 
185). 
 The higher frequency of chromosomal rearrangements (RET/PTC and PAX8-
PPARG) that we observed in MNPTCs when compared with SNPTCs, lead us to 
hypothesize that MNPTCs present a higher chromosomal instability than SNPTCs. This 
instability can cause chromosomal breakpoints leading to the formation of the fusion 
genes. This is reinforced by the observation of the co-expression for multiple molecular 
alterations in MNPTCs and not in SNPTCs– accumulation of RET/PTC rearrangement 
and BRAF mutation (p.V600E). The similar prevalence of BRAF and RAS mutations found 
in MNPTCs and SNPTCs supports the idea that point mutations is an event that occurs in 
the tumours independently of the hypothetical chromosomal instability.  
 We also observed that MNPTCs were significantly larger than SNPTCs, and 
patients with MNPTC tended to be older than patients with SNPTC, suggesting that 
MNPTCs can be “older” lesions that tend to accumulate molecular alterations along the 
tumoral development. One study reports the association between older age of the patients 
with recurrent PTC and the presence of multiple molecular alterations – RET/PTC 
rearrangement and BRAF mutation in the same tumour (126). In contrast, other studies 
report an association with young age of the patients and presence of multiple molecular 
alterations in the same tumour (127, 128).  
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 Two alternative explanations arise from our results. One possibility is that patients 
with higher level of genetic instability tend to develop multiple neoplastic nodules, 
presenting multiple molecular alterations (often chromosomal rearrangements and point 
mutations) in the tumours. One fact that supports the higher genetic instability of MNPTCs 
is the high frequency of chromosomal rearrangements detected in the MNPTCs - 
RET/PTC (78%) and PAX8/PPARG (33%), while in the SNPTC the frequency of 
chromosomal rearrangements was lower - RET/PTC (6%) and PAX8/PPARG (6%). 
Following this idea patients presenting SNPTC have a low level of genetic instability, 
showing only one molecular alteration (often point mutations), which lead to the 
development of a unique neoplastic nodule in thyroid gland. The other possibility is that 
MNPTC can represent older lesions, with a longer progression time, that have 
accumulated several genetic lesions. This explanation will fit with the older age of the 
patients and with the higher tumour size. 
 Summing up, we confirmed the distinctive genotype-phenotype signature 
presented in PTC, in which BRAF mutation (p.V600E) and RET/PTC rearrangements are 
associated to papillary growth pattern of PTC, and PAX8/PPARG and RAS mutations are 
restricted to follicular growth pattern of PTC. RET/PTC rearrangements and BRAF 
mutation (p.V600E) seem to represent subclonal events into tumour progression rather 
than the simultaneously occurrence of these molecular alterations at single-cell level. 
SNPTC and MNPTC showed distinct clinicopathological and molecular profiles. At 
variance to SNPTC, MNPTCs are larger, associated with older patients and presents 
often multiple molecular alterations, in which RET/PTC rearrangements are a frequent 
event. 
 The genotype-phenotype signature profile of oncocytic thyroid tumours stills 
unclear. FHCC is considered as a variant of FTC by the WHO (3), although other authors 
have describe FHCC as a separate entity (4). There are few studies reporting the 
presence of RET/PTC rearrangements in FHCA (46, 71, 72) and in FHCC (46, 71-73). We 
investigated the clinicopathological and genetic features of 3 FHCA and 17 FHCC (paper 
II). In our series of FHCT, RET/PTC rearrangements was significantly associated with 
solid pattern of growth in FHCC, in agreement with some previous reports (46, 71-73). 
 It was advanced that RET/PTC3 rearrangement are more prevalent in solid variant 
of PTC (65). Since the method we used to search for RET/PTC rearrangement does not 
allow to discriminate the rearrangement type, we do not know if RET/PTC3 is the 
rearrangement present in our cases of FHCC with solid growth pattern. 
 In fact, we do not know if the presence of RET/PTC rearrangement is more related 
with the cell characteristics of the follicular carcinomas, or more related with the solid 
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growth pattern of the carcinomas. As far as we are aware, RET/PTC rearrangements are 
nearly absent in every subtype of non-Hürthle FTC (follicular, solid or with other growth 
pattern). This fact suggests that the presence of the rearrangement may be associated 
with the Hürthle cell transformation of the neoplastic cells. However, it is intriguing that 
almost all the cases of our series of FHCC displaying RET/PTC rearrangements have a 
solid pattern of growth. On the other hand, if the rearrangement was indeed related to the 
Hürthle cell transformation, some positive cases should be found in our cohort of FHCC 
with a 'non-solid' pattern. To settle this controversy it would be necessary to search for 
RET/PTC rearrangements in a large series of non-Hürthle FTC with a solid growth 
pattern. 
 Three-quarters of the FHCC that scored positive for PAX8-PPARG showed 
follicular growth pattern. Previous reports did not find PAX8/PPARG rearrangements in 
FHCC nor in FHCA (110, 111, 119, 120, 122, 186, 187). The absence of PAX8/PPARG 
rearrangements in FHCC had been used to support the assumption that FHCC may 
develop via separate molecular events than non oncocytic FTC, thus representing a 
distinct type of thyroid neoplasm (111, 119). Our results show that the PAX8/PPARG 
rearrangement, which is particularly prevalent in FTA, FTC and FVPTC (37, 40, 120, 122), 
can also be present in FHCC. Additionally, BRAF mutations were not detected in our 
series of FHCT, similarly to previous reports (101, 102, 131, 134, 187-189). Only one RAS 
mutation (NRAS p.Q61K) was detected in a FHCC, confirming previous studies stating 
that RAS mutations are a rare event in FHCA and FHCC (119, 190-193). 
 Summing up, our results confirm the presence of RET/PTC rearrangement in 
FHCC and raise several questions about the putative clinicopathological meaning of such 
alteration in the neoplastic development. Furthermore, our results indicate, as previously 
advanced by others (46, 71-73), that RET/PTC rearrangement may be used as a genetic 
marker in the management approach of FHCC (23, 46, 194). FHCC are usually difficult to 
treat since they have a decreased iodine uptake and are thus less sensitive to radioactive 
iodine, a crucial treatment option for thyroid cancer. Tyrosine kinase inhibitors can 
specifically inhibit a number of tyrosine kinase enzymes, including RET/PTC (195). Our 
finding of RET/PTC rearrangements in the solid variant of FHCC turns this type of tumour 
a putative target for treatment with tyrosine kinase inhibitors. 
 The close genotype-phenotype association in the epithelial thyroid tumours is 
reinforced by our studies performed in rare and genetically uncharacterized cases. 
 A rare MSO case with diagnosis of FVPTC revealed positivity for the PAX8-
PPARG rearrangement and RAS mutation (p.Q61R) (paper III). A Pubmed search 
disclosed six articles reporting genetic alterations in SO (31, 196-200). No BRAF or RAS 
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mutations were found in BSO, and only one case presented a RET/PTC rearrangement 
(31, 196, 199). MSO cases can display BRAF and RAS mutations and RET/PTC 
rearrangements (196-200). Every MSO case presenting a cPTC phenotype had the BRAF 
mutation (p.V600E) (198, 199), and MSO with FVPTC phenotype can present BRAF 
mutations distinct from the classical BRAF mutation (p.V600E) – BRAF mutation (p.K601E 
and p.TV599-600M) (199, 200). BRAF mutation (p.K601E) has been previously described 
in cervical FVPTC (201), thus supporting the assumption that SO mimic cervical PTC in 
this aspect. The detection of PAX8-PPARG rearrangement and NRAS mutation in a MSO 
with FVPTC phenotype, as occurs in cervical epithelial thyroid tumours with predominant 
follicular morphology, reinforce the close genotype-phenotype relationship between these 
two molecular alterations and the follicular morphology of thyroid tumours. 
 We also reported a peculiar FTC case  with a glomeruloid growth pattern of the 
tumour (paper IV). Trying to situate the glomeruloid variant within the frame of the WHO 
classification of thyroid tumours (3), we know that the most distinctive molecular features 
of FTC are the high prevalence of PAX8-PPARG rearrangement and RAS mutations (2). 
The detection of the PAX8-PPARG rearrangement and RAS mutation (pQ61R) in this 
peculiar case with glomeruloid morphology supported the diagnosis of FTC. The detection 
of these genetic alterations together with local and vascular invasiveness of the tumour, 
absence of lymph node metastasis and distinct immunohistochemical features indicate 
this glomeruloid variant as a subtype of FTC rather than of PTC. Recently, a relapse of 
the FTC with glomeruloid growth pattern arose in the same patient, and the molecular 
analysis revealed again positivity for the PAX8-PPARG rearrangement and RAS mutation 
(pQ61R). These results reinforce the important and specific role of these genetic 
alterations in epithelial thyroid tumours with follicular growth pattern. 
 Additionally, we identified a germline PAX8-PPARG rearrangement in a patient 
with an autonomous hyperfunctioning FTC with angioinvasive behaviour (paper V). The 
tumour also harboured a somatic TSHR mutation (p.M453T) leading to a higher basal 
constitutive cAMP activity than the WT receptor (173). Mutations on TSHR gene or GNAS 
genes lead to constitutive activation of adenylyl cyclase and the formation of clonal 
hyperfunctioning FTAs. These mutations have been detected in a low frequency of FTCs 
(202-204), and most of those were autonomous hyperfunctioning FTCs (204-210). 
Constitutive activation of adenylyl cyclase may contribute, under certain conditions, to 
tumour progression (211). However, it does not seem sufficient for malignant 
transformation of thyroid follicular cells, and other genetic alterations are probably 
required to achieve cancer development. The unexpectedly observation of the PAX8-
PPARG rearrangements in 20% of the cells of the apparently normal thyroid tissue, of the 
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peripheral blood lymphocytes and of the uterine leiomyoma surgically removed 15 years 
before, raise the question of the role of PAX8-PPARG rearrangement in thyroid carcinoma 
development. Our results in the present case are consistent with the putative association 
between PAX8-PPARG rearrangement and angioinvasiveness in FTCs (111). The clinical 
importance of PAX8-PPARG rearrangement remains doubtful (176), however this result 
reinforce the specific role of PAX8-PPARG rearrangement in epithelial thyroid tumours 
with follicular growth pattern. The PAX8-PPARG rearrangement showed a mosaic 
distribution in tissues from both endodermal and mesodermal origins, which may indicate 
either a vertical transmission of the PAX8-PPARG rearrangement or one or more early 
embryonic mutation events. 
 Overall, our aforementioned works suggest a clear and specific role of the PAX8-
PPARG rearrangements in the development of well-differentiated follicular-cell derived 
thyroid tumours with predominant follicular growth pattern (Fig. 15) (paper I, II, III, IV and 
V). This association seems to be maintained even in epithelial thyroid tumours outside of 
cervical region – SO with diagnosis of FVPTC (paper III), and even in apparent FTC with 
an unusual morphology (paper IV). Additionally, the germline condition of the PAX8-
PPARG rearrangement in patients with FTC predominantly composed by follicular growth 
pattern seems to contribute for the tumour progression (paper V). Despite being widely 
disseminated that the RET/PTC rearrangements are largely associated with PTC (53), our 
works show that this association is not exclusive (Fig. 15). We found RET/PTC 
rearrangements in a high prevalence in FHCC with solid growth pattern, and even in 
FCHA (paper III). These findings also contribute for the discussion of the classification of 
oncocytic thyroid tumours: if should be considered as an independent group of epithelial 
thyroid tumours (4), or if should be maintained the current classification of FHCA and 
FHCC as subtypes of FTA and FTC (3), respectively. Additional data reveals that 
RET/PTC rearrangements have been detected in benign lesions of the thyroid (75), such 
as Hashimoto thyroiditis (73), weakening the possible close association of the RET/PTC 
rearrangement to the PTC. Also, we found the RET/PTC rearrangement in a CMVPTC 
from a patient with FAP familial condition (paper VII). These data reinforce the overlapping 
role of this rearrangement in several epithelial thyroid tumours, rejecting the idea that 
RET/PTC rearrangements is exclusively associated to specific phenotypes of epithelial 
thyroid tumours. 
 In addition to the chromosomal rearrangement present in epithelial thyroid 
tumours, our works revealed a clear association between the BRAF mutation (p.V600E) 
and the papillary growth pattern of PTCs (paper I), and RAS point mutations and follicular 
growth pattern of the FTTs (Fig. 15) (paper III and IV). However, BRAF and RAS 
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mutations are present in WDTC, PDTC and UTC (paper VIII), while RET/PTC and PAX8-
PPARG rearrangements are rarely found in PDTC and UTC, suggesting that thyroid-
specific rearrangements do not predispose cells to dedifferentiation (paper VIII). 
 
Figure 15. Schematic summary of genetic alterations associated with different growth patterns of the 
epithelial thyroid tumours. FHCA, follicular Hürthle cell adenoma; FHCC, follicular Hürthle cell carcinoma; 
FTA, follicular thyroid adenoma; FTC, follicular thyroid carcinoma; FVPTC, follicular variant of papillary thyroid 
carcinoma; PTC, papillary thyroid carcinoma. 
 
 Thyroid follicular epithelial cells are more likely to use the mechanism of DNA 
repair than to induce apoptosis in case of DNA damage, increasing the likelihood for 
formation of fusion genes through chromosomal rearrangements (164). The ability to 
detect fusion genes can be relevant for a correct diagnosis and for therapy. In our studies, 
a fusion gene microarray approach has been applied to epithelial thyroid tumours for the 
testing for 548 known cancer-associated fusion genes (paper VI). The usefulness of the 
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fusion gene microarray approach to detect fusion genes was validated, even in solid 
tumour samples, through the positive controls used – the TPC-1 cell line and two cPTCs 
positives for the RET/PTC1 rearrangement. The application of the fusion gene microarray 
approach in uncharacterized thyroid tumour samples was validated by the detection of 
PAX8-PPARG rearrangement as the top-scoring fusion gene in a FVPTC. The percentage 
of tumour cells (≤25%) positive for fusion genes can affect the discriminative capacity of 
the automated scoring algorithm used in the fusion gene microarray approach. Even 
recognizing this limitation, we used the top-ten highest scoring fusion genes of each 
sample of our series of thyroid tumours to search for additional fusion genes which might 
be novel to these tumours. Forty-nine of these fusion genes were nominated for further 
experimental work after visual inspection of the plots. We did not confirm the presence of 
other new fusion genes on epithelial thyroid tumours. This indirectly reinforces the idea 
that most fusion genes are specific to certain cancer types (paper IX). 
 The results we obtained in Part II may be seen in a double perspective. For one 
side, they may be considered as reinforcing the importance of the well-known fusion 
genes (e.g. RET/PTC and PAX8-PPARG) in thyroid tumorigenesis, as we studied in paper 
VI. On the other side, the methodology we have used in our study of thyroid tumours has 
a limited discriminative capacity for detection of fusion genes and therefore we intend to 
use high-throughput sequencing technologies in order to improve the detection of fusion 
genes and hopefully, be able to find novel rearrangements (see Future Perspectives). 
 
Summing up, in the present thesis we corroborated that: 
 BRAF mutations represent a diagnostic molecular marker of malignancy in 
epithelial thyroid tumours. Particularly, BRAF (p.V600E) mutation is close 
associated to PTCs with papillary or mixed growth pattern (papillary/follicular). The 
prognostic value of this mutation remains to be fully clarified; 
 PAX8-PPARG rearrangements are a useful molecular marker of epithelial thyroid 
tumours with follicular growth pattern. It is not, however, diagnostic of malignancy; 
 RET/PTC rearrangements and RAS mutations are associated with epithelial 
thyroid tumours with predominantly papillary and follicular growth pattern, 
respectively. Besides this genotypic-phenotypic association, RET/PTC 
rearrangements and RAS mutations are found in different types of benign and 
malignant epithelial thyroid tumours (for instance, RET/PTC in oncocytic follicular 
tumours) with variable frequencies. These findings reinforce that such genetic 
alterations cannot be identified, per se, as bona fide makers of histotype nor of 
malignancy. It seems necessary to progress in the understanding of the 
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etiopathogenic role of RET/PTC and RAS mutations to add to the equation several 
others players, such as other genetic alterations, as well as epigenetic and 
(micro)environmental factors. 
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 Notorious advances have occurred in recent years in the molecular 
characterization of epithelial thyroid tumours, but the etiopathogenic importance and the 
prognostic value of the known molecular markers remain unclear.  
 In an attempt to clarify the usefulness of the mentioned genetic alterations, 
extensive studies for the characterization of the known genetic alterations in large series 
of thyroid tumours are needed, doing a rigorous histopatologic classification of the 
tumours and a meticulous follow-up of the patients. Due to the known heterogeneity of 
epithelial thyroid tumours, the different morphologies present in the tumours should be 
described in detail, correlating this information with genetic alterations detected by 
different approaches – RT-PCR, DNA sequencing, FISH and Southern blot approaches as 
examples. Additionally, the genetic alterations detected in the tumours should be 
determined if they represent clonal or subclonal events, in order to clarify clinical meaning 
of these molecular markers. 
 In the last years, PAX8-PPARG rearrangements have been set as a genetic 
marker of epithelial follicular tumours, apparently being more frequent in FTC than in 
FVPTC and FTA. The results we have obtained indicate a close association of PAX8-
PPARG rearrangements and follicular morphology of the epithelial thyroid tumours. 
Additionally, the previous results of our group indicate a similar percentage of positivity for 
PAX8-PPARG rearrangements in FTA, FTC and FVPTC cases. We intend to study a 
large series of FTA, FTC and FVPTC specifically looking for PAX8-PPARG 
rearrangements, with a detailed and rigorous clinicopathological data of the cases, in 
order to clarify the potential clinical importance of this genetic marker. 
 Around 40% of epithelial thyroid tumours still remain without any identified 
molecular alteration. Our attempt to detect new fusion genes in thyroid tumours using an 
oligo microarray approach allowing the detection of 548 know and putative fusion genes 
was unsuccessful to this respect. To find new fusion genes not yet described in thyroid 
tumours, we are starting a new project using high-throughput paired-end RNA sequencing 
in thyroid tumours. In case new fusion genes are detected in thyroid tumours, this finding 
may provide new molecular markers that may carry prognostic and/or therapeutic value. 
 Chromosomal rearrangements lead to the abnormal formation of fusion genes 
being some of them cancer type-specific. Besides these structural chromosomal 
6 Future Perspectives 
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alterations, aneuploidy is a numerical chromosome alteration that can also cause cancer. 
Aneuploidy and chromosomal instability (CIN) are hallmarks of cancer. Centrosome 
amplification can lead to multipolar spindle formation which contributes to aneuploidy and 
CIN. Activated RAS oncogene has been suggested to promote CIN. Taking into account 
previous results obtained by our group, we intend to investigate how RAS can lead to 
centrosome amplification and aneuploidy, as well as how cells divide in the presence of 
extra centrosomes by live-cell imaging. We would also like to explore the molecules 
involved and the underlying molecular mechanisms in aneuploidy and CIN by performing 
a genome-wide cDNA array. 
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